B.A.C.R. Abstracts of member proffered papers by unknown
Br. J. Cancer (1980) 41, 168
BRITISH ASSOCIATION FOR CANCER RESEARCH
21st ANNUAL GENERAL MEETING
Held at the University of Southampton 31 March-2 April 1980ABSTRACTS OF MEMBERS PROFFERED PAPERS
ABSTRACTS OF MEMBERS' PROFFERRED PAPERS
BREATH ANALYSES OF 14CO2 PRO-
DUCTION FROM 14CH3-LABELLED
HEXAMETHYLMELAMINE IN THE
MOUSE. A. GESCHER & T. RAYMONT,
Cancer Chemotherapy Research Group, Univer-
sity of Aston, Birmingham
The antineoplastic drug hexamethylmel-
amine (HMM) requires metabolic activation,
and its activity depends on the presence of
methyl moieties in the molecule. It is bio-
transformed in the liver by N-demethylation,
following which the single carbon moiety
enters the formaldehyde-formate pool and is
mainly excreted as CO2. As part of our in-
vestigation into the relationship between
HMM metabolism and its mode of action we
determined 14CO2 exhalation in a continual
fashion in CBA/Lac mice (20-30 g) following
i.p. administration of 14CH3-labelled HMM
(40 mg/kg) and compared it with the 14CO2
appearance in breath after 38 mg/kg 14CH3-
labelled aminopyrine (AP), a non-cytotoxic
model substrate of N-demethylases. Whereas
the 14CO2 formation rate-time plot for AP
peaked rapidly and declined in a biphasic
fashion, the corresponding plot for HMM
showed a peak after 40-70 min and a mono-
phasic decline with a halflife (tl) of89-7 + 6-6
min (n=5). Peak N-demethylating activity
produced 82-5 + 8-0 nmol 14CO2/min (n=4)
after AP and 354 + 45 nmol 14CO2/min
(n=4) after HMM. Pretreatment with an
inhibitor of oxidative drug-metabolizing en-
zymes (SKF525A, 60 mg/kg i.p. 30 min
before drug administration) and an enzyme
inducer (phenobarbital, 50 mg/kg i.p. for 4
days) dramatically effected the CO2 data.
For HMM the t' of the 14CO2 in the breath
after SKF was increased to 264-5 + 21-7 min
(n=3); in phenobarbital-pretreated mice the
t-was decreased to 69-3 + 107 min (n=4).
These results show that pharmacogenic
interference with oxidative drug metabolism
leads to changed HMM demethylation rates
in vivo which may influence its antineoplastic
efficacy.
CLINICAL AND EXPERIMENTAL
STUDIES WITH PENTAMETHYLMEL-
AMINE (PMM). D. R. NEWELL, C. J.
RUTTY, J. F. R. MUINDI, I. E. SMITH & K. R.
HARRAP, Dept of Biochemical Pharmacology,
Inst. of Cancer Res., Sutton, Surrey
PMM is a water-soluble melamine derivative
which, unlike hexamethylmelamine (HMM),
can be administered clinically in parenteral
form. In the present Phase I clinical study
PMM was given as an i.v. infusion (100 mg/
m2_1300 mg/M2). Gastrointestinal toxicity
(nausea and vomiting) was the major side-
effect observed, as with HMM given orally,
which became severe and prolonged (24 h) at
doses > 300 mg/M2. Pharmacokinetics and
metabolism were monitored in patients by
gas chromatography using a nitrogen-specific
detector. PMM is eliminated from the plasma
with a half-life of 108 min. Two major PMM
metabolites were detected in plasma:
N2N2N4N6-tetramethylmelamine and N2N4-
N6-trimethylmelamine. Pharmacokinetic
analyses indicate that i.v. PMM produces
higher levels of less extensively demethylated
melamines than HM:M administered orally.
Hence it may be possible, using PMM, to
achieve therapeutic levels of active metabo-
lites at doses xvhich are non-toxic to normal
host tissues. Thus PMM may offer a significant
therapeutic advantage over HMM. In addi-
tion, preliminary evidence from high-perform-
ance liquid chromatography analyses sug-
gests the presence of N-methylolmelamines
in human plasma. Such compounds are
chemically unstable in aqueous solution,
releasing formaldehyde at a rate which is
highly dependent upon the ionic environ-
ment. N-methylolmelamines are more toxic
to a number of tumour cell lines in vitro than
are the corresponding methylmelamines, and
thus may represent the species responsible
for the in vivo antitumour activity. N-
methylolmelamines markedly inhibit both
DNA and RNA synthesis in vitro, as does
formaldehyde. However, these inhibitory
effects do not appear to be responsible for the
selective cytotoxic action in vivo, where in-
hibition of nucleic acid synthesis in sensitive
tumour cells cannot be shown.
PRECLINICAL STUDIES ON POTEN-
TIAL SECOND-GENERATIONALTER-
NATIVES TO CISPLATIN (CisPtII),
K. R. HARRAP, M. JONES, R. SHEPHERD,
H. MCD. CLINK, S. SPARROW, B. C. V.
MITCHLEY, S. A. CLARKE & A. VEASY, Dept
Biochem. Pharmacol., Inst. Cancer Res.,
Sutton, Surrey
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Cis-dichlorodiammine platinumn (II) (cis-
platin) is useful in the treat-ment of hiuman
malignant disease. However, its therapeutic
effectiveness is limited by the appearance of
severe dose-limiting toxic side-effects. These
include nephrotoxicity, myelotoxicity, severe
nausea and vomiting and ototoxicity. There
is a great need to replace cisplatin with a less
toxic derivative possessing antitumour
activity at least comparable to that of cis-
platin. To this end we have selected 8
platinum complexes from more than 300
derivatives previously screened for anti-
tumour activity at the Institute of Cancer
Research. These 8 compounds all possess
antitumour activities comparable to or greater
than that of cisplatin in several rodent
tumour systems.
The selected platinum complexes were
screened against a wider spectrum of trans-
plantable animal tumours, and against a
human epidermoid carcinoma ofthe bronchus
grown in immune-deprived mice. Toxic
damage to normal tissues was assessed in the
rat at maximum tolerated doses of each
compound. A biochemical indicator of tissue
damage, platinum-induced nuclear protein
phosphorylation, was also measured in
tumour and several host tissues.
Our overall conclusion from this study is
that cisdiammine- 1,1-cyclobutane dicarb-
oxylic acid (CBDCA) exhibits more selective
antitumour activity than any of the other
derivatives. This compound is a viable candi-
date for Phase I clinical evaluation, and an
appropriate toxicology study is in hand.
REDUCTION OF THE CYTOTOXICITY
OF HYDROXYMETHYL TRIAZENES
BY ESTER OR ETHER FORMATION.
J. A. HICKMAN, R. J. SIMMONDS, Department
of Pharmacy, University of Aston, Birming-
ham, G. F. KOLAR, D.K.F.F., 6900 Heidel-
berg, F.R.G. & K. VAUGHAN, Department of
Chemistry, St Mary's University, Halifax,
Nova Scotia
The N-dimetlhyltriazines are metabolized to
selective antitumour species, and it has been
proposed that the hydroxymethyl inter-
mediates of their metabolic N-demethylation
may be important for selective cytotoxicity
(Hickman, 1978, Biochimie, 60, 997). Preuss-
man et al. (1969, Biochem. Pharmacol., 18, 1)
have suggested that conjugates of hydroxy-
methyltriaz nes may be transport forms of
biologically active species, and Kolar &
Carubelli (1979, Cancer Lett., 7, 209) recently
reported the isolation from rat urine of a
novel 0-glucuroniside conjugate after ad-
ministration of 3,3-dimethyl-1-(2,4,6-tri-
chlorophenyl)triazene. We have now investi-
gated the cytotoxic and antitumour proper-
ties ofthis conjugate. In an in vivo antitumour
test against the TLX5 lymphoma in CBA/
LAC mice 50 mg/kg of the conjugate had no
activity whereas 50 mg/kg of the precursor
dimethyltriazene gave up to 62% increase in
lifespan. Invitrotheconjugate had no toxicity
at 1 mg/ml, wNhereas the monomethyl ana-
logue was potently cytotoxic at 50 Kg/ml.
Our failure to synthesize the hydroxymethyl
analogue prevented a direct comparison
between this compound and its conjugate;
however, p-carbomethoxy-N-hydroxymethyl-
N-methylphenyltriazene was active in vivo,
whereas its O-benzoylated derivative had
reduced activity. The results suggest that
substitution of hydroxymethyltriazines may
be a deactivation step in the metabolism of
dimethyltriazenes.
THE TOXICITY OF BINARY COM-
BINATIONS OF 2'-DEOXYCOFOR-
MYCIN (dCf) AND 2'-DEOXYADEN-
OSINE (AdR). R. M. PAINE, H. McD.
CLINK, K. G. MCGHEE & K. R. HARRAP, Dept
Biochem. Pharmacol., Inst. Cancer Res. and
Dept Haematology, Royal Marsden Hospital,
Sutton, Surrey
A Phase I clinical study of dCf showed in-
hibition of lymphocyte adenosine deaminase
(ADA) activity, lymphocytotoxicity and large
elevation in erythrocyte deoxyadenosine
triphosphate (dATP). The latter effect re-
flected increased circulating purine levels
following treatment, and suggested that AdR
might be used clinically to enhance dCf
activity. We have previously shown that
dCf potentiates the cytotoxicity of AdR in
vitro (Paine etal., 1977, Br. J. Cancer, 36, 417).
The underlying biochemical mechanism ap-
peared to be via the intracellular accumula-
tion of dATP, a known negative effector of
the enzyme ribonucleotide reductase. The
present study shows, however, that dCf/AdR
combination can prove prohibitively toxic to
normal tissues.
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Treatment of mice with dCf (0-27 mg/kg)
for 5 days inhibited spleen and lymphnode
ADA, a 64-fold elevation of erythrocyte
dATP, but no haematological toxicity or
weight loss. However, if mice were injected
with AdR (270 mg/kg) in combination with
dCf, weight loss, haematological toxicity and
liver damage occurred. Leucopenia was pro-
nounced, often with agranulocytosis. The
femoral marrows of these mice showed cyto-
toxic damage, including vacuolation and
some giant metamyelocytes. Erythrocyte
dATP levels were raised 1500-fold. Mortality
during treatment was attributable to acute
liver failure; marrowr toxicity was only
detected when treatment had finished. No
such toxic effects were seen in mice receiving
adenosine (AR, 270 mg/kg) in combination
with dCf, AR alone, or AdR alone. We con-
clude that the supplementation of clinical
dCf schedules with AdR should be considered
with caution.
THE EFFECTS OF NANDROLONE
DECANOATE (DECA - DURABOLIN,
ORGANON) ON THE TOXICITY AND
ANTI-TUMOUR ACTION OF CCNU
IN EXPERIMENTAL MOUSE COLON
TUMOURS. J. A. DOUBLE & M. C. BIBBY,
Postgraduate School of Studies in Medical and
Surgical Sciences, University of Bradford
There are conflicting reports in the literature
on the value of anabolic steroids in the man-
agement of patients undergoing cancer
chemotherapy. This situation almost cer-
tainly arises from variation in dose and treat-
ment schedules. Most reports describe simul-
taneous treatment with low doses of ana-
bolics, which appear to be of no value. The
Bradford group have maintained that in
order to achieve clinical benefits it is neces-
sary to pretreat the patients with high doses
of anabolics (Hancock et al., 1977, Br. J.
Surg., 64, 134). Clinically, nandrolone de-
canoate (N.D.) appears to reduce the toxicity
of various cytotoxic agents. The present
study is an attempt to transfer a clinical im-
pression to numerical data, using an experi-
mental model system. The spectrum of
chemotherapeutic sensitivity to standard
agents of the mouse adenocarcinoma of the
colon (MAC) system has been shown to be
similar to human large-bowel cancer (Double
& Ball, 1975, Cancer Chemother. Rep., 59,
1083). Therapeutic indices are low and re-
sponses are only seen close to maximum
tolerated dose. We have shown that 7-day
pretreatment with N.D. raises the LD50 of
CCNU from 78 mg/kg to 112 mg/kg. It could
be argued that this was a generalized reduc-
tion in the potency of the cytotoxic agent.
Results from combined toxicity and anti-
tumour studies using the MAC 13 line and
CCNU however have shown that the anti-
tumour action of the cytotoxic agent is un-
altered by the presence of N.D. Simul-
taneous treatment writh N.D. and CCNU
produces a therapeutic index of 1-1, wlhereas
7-day pretreatment with N.D. before CCNU
produces a therapeutic index of 1-7. Further
studies on this phenomenon are under way
using other agents and other tumour lines.
EFFECT OF PREDNISOLONE ON
CHROMATIN BINDING OF ALKYL-
ATING AGENTS. P. J. THRAVES, R.
SHEPHERD. A. JENEY & K. R. HARRAP,
Dept of Biochem. Phar,nacol., Inst. of Cancer
Res., Sutton, Surrey
Prednisolone enhances the selectivity of
chlorambucil byreducing its systemic toxicity
and enhancing tumour-cell kill (Harrap et al.,
1977, Eur. J. Cancer, 13, 873). The present
studies demonstrate that although predniso-
lone does not enhance the overall macro-
molecular binding of 3H-chlorambucil in vivo,
it does modify its binding to specific chroma-
tin fractions in a tissue-selective manner.
Binding was increased in chromatin fractions
of both alkylating-agent sensitive and re-
sistent strains of Walker 256 carcinosarcoma,
but reduced in the corresponding fractions
from intestinal mucosa. In vitro, prednisolone
enhanced the binding of i4C-mephalan to
soluble chromatin in resistant cells, but did
not alter gross macromolecular binding. The
highest concentration of bound drug was in
the insoluble chromatin fraction. About 30%O
of chromatin-bound drug was released after
DNase II digestion. Chlorambucil treatment
enhanced the digestion of chromatin by
micrococcal nuclease, as demonstrated by
sucrose-density-gradient fractionation. Chlor-
ambucil appeared to bind preferentially to
internucleosome chromatin.
These data demonstrate that the enhanced
selectivity of clhlorambucil in the presence of
prednisolone is associated with tissue-specific
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modulations of chromatin binding, and that
internucleosome linker regions and insoluble
structural chromatin are major alkylating-
agent-binding sites.
CYTOSINE ARABINOSIDE (ARA-C)
DEAMINATION IN HUMAN LEUK-
AEMIC MARROW AND RESISTANCE
TO ARA-C. A. L. HARRMS & D. G. GRAHAME-
SMITnI, MI.R.C. Clinical Pharmacology Unit,
Radcliffe Infirmary, Oxford. (Introduced by
Prof. A. J. S. Davies)
Ara-C is an effective drug ill acute myeloid
leukaemia (AML). Used alone remission
occurs in only 25-470/0 of patients (Armen-
trout & Burns, 1974, Am. J. MIed. Sci., 268,
163). Ara-C is converted intracellularly to its
active metabolite Ara-CTP in AML myelo-
blasts, and also deaminated to Ara-U, an
inactive metabolite. High deaminase activity
in lysed marrow blasts has been associated
writh clinical resistance to Ara-C (Steuart &
Burke, 1971, Nature (New Biol.), 233, 109)
but this was not found with intact peripheral
blasts (Smyth et al., 1976, Eur. J. Cancer, 12,
567).
Intactmarrowr myeloblasts from 11 patients
w,ith newly diagnosed untreated AML were
incubated w%ith (3H)-Ara-C (1 nM-100 [kM) for
45 min at 37°C in Eagle's medium.(3H)-
Ara-CTP and (3H)-Ara-U production was
measured, with and without 1mM tetra-
hydrouridine (THU) a potent deminase in-
hibitor. The sensitivity of DNA synthesis to
Ara-C was measured using inhibition of (3H)-
TdR incorporation into DNA by 10nM-10jtM
unlabelled Ara-C, incubated under identical
conditions (+ THU). The ratios of Ara-U/
Ara-CTP ranged from 0-32 to 19-11. THU
increased Ara-CTP production by 0-270 and
deamination was completely inhibited. The
increase in Ara-CTP was not related to Ara-
U/Ara-CTP ratio, but to 0/ deamination of
medium in absence of THU (Corr. 0-89,
P<0-001). 500o inhibition of DNA synthesis
was produced by 30-100nM Ara-C, and at
1 ,uM 800O inhibition occurred in all blasts.
THU did not increase the sensitivity to Ara-C.
These results show that Ara-C was freely
available to both metabolic pathways, and
that deainination does not produce resistance
to Ara-C by diverting Ara-C intracellularly
from the kinase pathway that produces Ara-
CTP.
THE DESIGN AND SYNTHESIS OF A
NOVEL FOLATE ANTIMETABOLITE
N-(4 -(N-((2-AMINO -4-HYDROXY -6-
QUINAZOLINYL) METHYL) PROP-2
YNYLAMINO)BENZYL)-L-GLUTAMIC
ACID (CB 3717). T. R. JONES, A. H.
CALVERT, A. L. JACKMAN & K. R. HARRAP,
Dept Biochem. Pharmacol., Inst. Cantcer Res.,
Sutton, Surrey
Critical examination of the folate enzyme
network suggests the need for a folate in-
hibitor of thymidylate synthetase (TS) which
should give an antimetabolite superior both
to methotrexate (MTX) and to 5-fluorouracil
(FU) for the following reasons: (i) TS is the
rate-limiting enzyme in the thymidylate
cycle; (ii) the antipurine effect of MTX,
causing gut toxicity in mice but contributing
little to the antitumour effect, is avoided
(Harrap et al., 1977, Chem. Biol. Interact., 18,
119); (iii) a folate analogue does not require
metabolic activation; resistance to FU is
frequently due to the deletion ofits activating
kinase; (iv) unlike FU, there should be no
incorporation into RNA with an associated
toxicity; (v) the competing metabolite, 5,10-
methylene-tetrahydrofolate, lies at a meta-
bolic branch point and might not build up to
overcome the block; (vi) Having a different
locus ofaction from MTX the agent should be
active against MTX-resistant cells which have
raised intracellular dihydrofolate reductase.
We have achieved this aim, and report here
the design and synthesis of 2 new 2-amino-4-
hydroxy-quinazoline antifolates. Progressive
unsaturation of the terminal C-C bond of a
3-carbon substituent at N-10 increases the
affinity of the compounds for TS. The 5000
inhibitory concentrations were: 170nM
(propyl); 69nM (allyl); 5nM (propargyl). This
last named, CB 3717, is the most potent
inhibitor of TS yet described. Some of its
biochemical and antitumour properties are
outlined in the next paper.
BIOLOGICAL PROPERTIES OF A
NOVEL FOLATE ANTIMETABOLITE
(CB 3717). A. H. CALVERT, A. L. JACKMAN,
T. R. JONES & K. R. HARRAP, Dept Biochem.
Pharmacol., Inst. Cancer Res., Sutton, Surrey
This compound w%Nas developed as an anti-
tumour agent acting by inhibition of thymi-
dylate synthetase (TS, EC 2.1.1.45). The in-
hibition of TS (purified by affinity chromato-
172ABSTRACTS OF MEMBERS' PROFFERED PAPERS
graphy from L1210 cells) by CB 3717 was
characterized, and found to be competitive
with 5,10-methylenetetrahydrofolate. The Ki
was 1-2nM, making CB 3717 the most potent
TS inhibitor described. Reversal of cyto-
toxicity to L1210 cells in culture could be
achieved by co-incubation with thymidine,
suggesting that TS was the effective locus. A
cell line (L1210/R7A), resistant to metho-
trexate (MTX) due to raised intracellular
dihydrofolate reductase (DHFR) was not
significantly cross-resistant to CB 3717.
Since MTX resistance may also occur by
reduction ofthe active transport ofMTX, the
transport of CB 3717 was investigated. It
appeared that CB 3717 may be transported by
a different pathway to MTX (possibly that
used by folic acid) since: (a) CB 3717 com-
peted with labelled folic acid for transport
into L1210 cells; and (b) A cell line, L1210/
R3U, resistant to MTX due to both increased
DHFR and decreased MTX transport, was
not substantially cross-resistant to CB 3717.
Dramatic antitumour effects, with minimal
toxicity, were observed in animals bearing the
L1210 tumour. The ascitic tumour was cured
in 90%O of animals, and significant increases
in lifespan were seen after i.v. iinjection ofthe
tumour. In both cases the results were better
than those obtained with an optimal schedule
of MTX. Activity was also seen against the
ADJ/PC6 tumour, which is normally found
to be refractory to antimetabolite treatment.
Toxicological evaluation of CB 3717 is
planned with a view to early clinical study.
CHEMOSENSITIVITY OF HUMAN
BREAST - TUMOUR XENOGRAFTS.
M. J. BAILEY, I. SMITH & G. STEEL, Bio-
physics Department, Institute of Cancer Re-
search, Sutton, Surrey
Eight lines of human breast cancer have been
established and serially transplanted in
immune-deprived mice. 5 of these lines have
been tested for chemosensitivity to the cyto-
toxic agents clinically active against breast
cancer, using tumour growth delay as an
end-point. The tumours varied considerably
in their drug sensitivity, some lines being
generally chemosensitive, whilst others
showed little response to any agent. The order
in which drugs and drug combinations were
ranked remained constant in repeated experi-
ments on each line, but differed from one line
to another. In all eases, a combination of
drugs was more effective than the single
agents in that combination at equitoxic
doses. By studying dose-response curves of
single agents, new drug combinations may be
designed. One such combination (adriamycin
plus melphalan) proved to be very effective
when tested against 3 of the xenograft lines.
This system may be useful in testing new
agents and predicting new combinations for
clinical use against breast cancer.
ENHANCEMENT OF RAZOXANE
ANTITUMOUR ACTIVITY BY CIM-
ETIDINE. M. M. COLLINS (introduced by K.
Hellman), Department of Cancer Chemo-
therapy, Imperial Cancer Research Fund,
London WC2
Razoxane [± 1,2 di (3,5-dioxopiperazine-1-yl)
propane] is a non-selective inhibitor ofmitosis
(Bakowski, 1976, Cancer Treat. Rev., 3, 95).
It is active by mouth and soluble in dilute
HCI. To investigate whether gastric acidity
had any influence on the subsequent fate and
activity of the compound on experimental
tumours, cimetidine was given in anticipation
that the antitumour effect of razoxane would
be appreciably diminislhed. In the event the
opposite occurred.
Female Sprague-Dawley rats were inocu-
lated with Walker carcinosarcoma and pre-
treated with cimetidine 1 h before adminis-
tration of razoxane. The antitumour effect of
razoxane in these rats was significantly
greater than in those treated with razoxane
alone (P<005). Cimetidine alone possessed
no significant antitumour activity. The ex-
periments have been repeated 4 times and the
results have been similar on each occasion.
It is clear therefore that gastric acidity is
not important to the antimitotic activity of
razoxane. Whether the enhanced activity of
razoxane after cimetidine might be due to
increased blood levels of razoxane or other
mechanisms is not yet resolved.
METHOTREXATE WITH INOSINE,
THYMIDINE AND ALLOPURINOL
RESCUE. A PHASE I CLINICAL
STUDY. P. J. DADY, G. A. TAYLOR & K. R.
HARRAP, Dept of Biochem. Pharmacol., Inst.
of Cancer Res., Sutton, Surrey
Mice are rescued from the toxic effects of
methotrexate (MTX) by a combination of
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inosine, thymidine and allopurinol (ITA);
antitumour activity is superior to that of
MTX with folinic acid (FA) rescue (Harrap
et al., 1977, Chem.-Biol. Interactions, 18, 119).
32 patients were treated in a Phase I clinical
study of ITA rescue. Initially ITA, without
MTX, was given to 9 patients. Then 400 mg/
m2/24 h MTX was infused into 17 patients
and ITA, in decreasing doses, was given at
the end of these infusions. A 'minimum safe
rescue" was identified. In 6 patients the dose
of MTX w%as then increased in stages to 1-5 g/
m2/24 h.
No toxicity was seen with ITA alone, nor
when MTX 400 mg/M2/24 h was followed by
rescue infusions of more than: inosine 0-2 g/
m2/24 h, TdR 1 g/m2/24 h and allopurinol
200 mg 8-hourly. Below this 'minimum safe
rescue", myelosuppression, mucositis and
skin rashes were seen, even though rescue
was continued until circulating MTX had
fallen to 6 x 10-8M. With 800 mg/m2/24 h
MTX '*minimum safe rescue" was successful,
but when MTX 1P5 g/m2/24 h was used,
toxicity occurred in spite of rescue. MTX-
related skin lesions were more frequent than
would be expected with the MTX plasma
levels achieved. This study showed that ITA
is not in itself toxic and the "minimum safe
rescue" is effective from MTX doses up to at
least 800 mg/M2/24 h.
A VERSATILE HIGH-PERFORMANCE
LIQUID CHROMATOGRAPHIC (HPLC)
METHOD FOR THE ESTIMATION OF
PURINES, PYRIMIDINES AND THEIR
CONGENERS. G. A. TAYLOR, P. J. DADY,
A. S. GRIMES & K. R. HARRAP, Dept of
Biochem. Pharmacol., Inst. of Cancer Res.,
Sutton, Surrey
A method was developed for the estimation
of purines, pyrimidines and their congeners
in the plasma ofpatients included in a Phase I
clinical study of thymidine (TdR)/inosine
(IR)/allopurinol (Ap) (ITA) reversal ofmetho-
trexate (MTX) toxicity. An initial isocratic
reverse-phase HPLC separation allowed the
collection of a number of effluent fractions,
each containing a single component of in-
terest, together with a limited number of
unknown contaminants. the reapplication of
these fractions to a second HPLC separation
permitted the resolution and quantitation of
the components of interest.
Circulating levels of nucleosides and bases
were measured in patients' plasmas, and in
samples from healthy human volunteers.
Patients' pretreatment levels of hypox-
anthine (HX) fell into 2 distinct groups: the
majority (20/25) were in the range 0-85-
6-5 )uM, but 5/25 ranged between 49 8 and
64-2 [kM (mean 52-4 + 2.3). The "low" HX
group (mean 2-62 + 0-32 MM) had significantly
higher levels of circulating HX (P=0.006)
than healthy humans (1-62 + 0 2 tkM). Follow-
ing its oral administration, Ap was rapidly
metabolized to oxypurinol, which circulated
at high levels ( 10-4M) for considerable
periods ( > 6 h). During the administration of
the "minimum safe rescue" of ITA, no
significant elevation of HX, thymine (T) or
TdR was observed. At higher rescue doses
TdR was metabolized to T with a half-life of
14-20 min; HX possessed a half-life of 40-65
min.
The method has a high sensitivity; it has
also been applied to enzyme assays (e.g.
xanthine oxidase, dihydrothymine dehydro-
genase) and to the purification of labile
radioactive materials.
DETECTION OF RADIOIODINATED
TUMOUR - SPECIFIC ANTIGENS
WITH SYNGENEIC ANTISERA. D.
HANNANT*, J. G. BOWENt, M. R. PRICE* &
R. W. BALDWIN*, *Cancer Research Cam-
paign Laboratories, University of Nottingham
and tBoots Co., Nottingham
Lectin affinity andimmunoadsorbent chroma-
tography were used to purify papain-
solubilized tumour-specific antigens (TSA)
from the aminoazo dye-induced rat hepatoma
D23. Isolated antigens were radioiodinated
using procedures which included (a) coupling
of 1251-labelled tyrosine to TSA with a
carbodiimided reagent, (b) protection of
antigenic determinant by labelling TSA
while bound to its syngeneic immunoadsor-
bent. These radiolabelled antigens retained
serological activity, as demonstrated by co-
precipitation (double antibody) tests and
specific rebinding to syngeneic immuno-
adsorbents. Immunoadsorption chromato-
graphy indicated that one consequence of
radio-labelling hepatoma D23 TSA with 1251
was to reduce the affinity of the labelled
antigen for its syngeneic specific antibody.
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DETECTION OF HOST IMMUNE RE-
SPONSE TO A TRANSPLANTABLE
TUMOUR IN THE RAT BY THE LAI
ASSAY. C. M. BALLARD & J. P. DICKINSON,
YCRC Laboratories, University Department of
Radiotherapy, Cookridge Hospital, Leeds
The modified capillary-tube leucocyte ad-
herence inhibition (LAI) assay (Ballard &
Dickinson, 1980, Clin. Exp. Immrunol., 40)
has been used to monitor host immune
response to a transplantable mammary
carcinoma of spontaneous origin in the rat
(Moore & Dixon, 1977, Cell Tissue Kinet, 10,
583). Animals were inoculated with either
viable or non-viable (irradiated) minced
tumour. Blood was collected by cardiac punc-
ture at various times after inoculation. 3M
KCI extracts of tuimour and liver were used
in the assay. Leucocytes from control
animals (untreated, or injected with 0-9%o
NaCl only) showed a weak, nonspecific, con-
centration-dependent inhibition of adherence
with both extracts, similar to the responses
obtained when other proteins (e.g. KLH,
PPD, FCS, BSA) are added to a leucocyte
suspension. A very strong additional inhibi-
tion of leucocyte adherence with tumour
extract was obtained soon after inoculation
in both tumour-bearing and irradiated-
tumour-bearing animals. This was maintained
throughout the experimental period in irradi-
ated-tumour-bearing animals, but declined as
the tumour enlarged in tumour-bearing
animals. Throughout the period, responses of
both groups of animals to liver extract re-
mained similar to responses of control
animals. No LAI effect was observed when
leucocytes from control animals were pre-
incubated with plasma from tumour-bearers
and irradiated-tumour-bearers. The results
show a specific recognition of tumour by the
host; however, recognition does not imply an
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0 N
100 N
50 Im
100 Im
150 Im
Exp. 1
Meani spleen index
A
No tumour Tumour
149 1*14
2-15 1-67
.1-86 1-55
2-22 1-38
effect on tumour growth. Heavy tumour
load was found to lead to abrogation of this
response. The LAI assay has been found to
be a simple and reliable method for detection
and monitoring of one aspect of the host
cellular response to the presence of malignant
disease.
PRESENCE OF A TUMOUR IN F1
HYBRID MICE PARTIALLY INHIBITS
THE INDUCTION OF GVHD AFTER
INJECTION OF PARENT LINE ICC.
T. WHITMARSH-EVERISS & M. 0. SYMES,
Department ofSurgery, University of Bristol
In (AxCBA(T6)Fl hybrid mice, GVHD was
induced by i.v. injection of A spleen cells, on
Day 0. One half of the hybrid mice had re-
ceived an s.c. transplant of an (AxCBA)Fl
strain tumour on Day -9. The mice were
killed on Day 14 and their spleen ratios (wt
of spleen/g body wt) and spleen indices
(spleen ratio of mouse receiving parent-line
cells/mean spleen ratio of uninjected mice or
mice receiving tumour cells only) determined.
The presence of a tumour reduced GVHD in
2 experiments (see Table).
There was no difference in tumour weight,
at Day 14, between the several groups of
tumour-bearing animals receiving spleen cells.
Thus inhibition ofGVHD may not depend on
diversion of the spleen cells to attack the
tumour.
REGIONAL IMMUNOTHERAPY OF
GUINEA-PIG LINE-10 HEPATOMA
WITH CHEMICAL HYPERSENSI-
TIZERS. M. V. PIMM*, R. W. BALDWIN*,
W. A. BASLEY* & V. S. BYERSt, *Cancer
Research Campaign Laboratories, University
of Nottingham and tDept Dermatology, Univ.
ofCalifornia, U.S.A.
p
NS
< 0 05
NS
< 0-001
Exp. 2
Mean spleen index
No tumour Tumour J)
1-58 0-87 < 0 001
1-94 1-30 <0001
2-53 1-82 < 0 001
N = non-immune. Tm = immune to (AxCBA)Fl tumour. 5-8 animals/group.
12
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Regional immunotherapy in which agents
are administered to localize within tumour
deposits and promote local host responses,
including hypersensitivity reactions, is being
widely evaluated for cancer therapy. Origin-
ally intact bacteria (principally BCG and
C. parvum) were used, but these have toxic
side-effects, and attention is now directed to
developing more defined agents.
The present studies are evaluating regional
immunotherapy with alkylcatechols related
to the natural plant oil urushiol. These were
chosen because they are highly potent hyper-
sensitizing agents with marked lipophilicity
(Byers et al., 1979, J. Clin. Invest., 64, 1437).
With intact viable rat and guinea-pig
hepatoma cells, 3H-3-n-pentadecylcatechol
(PDC) became incorporated into cell mem-
branes on in vitro incubation. Intradermal
growth of the guinea-pig Line-10 hepatoma
was restricted by intralesional injection of
PDC or urushiol, and there was a concomitant
control of lvmphnode metastases. Although
effective in DMSO solution, the response was
considerably enhanced when PDC was given
in a lipid solvent (squalene). Pre-induction of
contact sensitivity to PDC also enhanced the
therapeutic response.
These studies demonstrate that chemically
defined agents, inducing T-lymphocyte-
mediated delayed-hypersensitivity responses,
can be used for regional tumour immuno-
therapy.
SUPPRESSOR CELLS IN RATS IM-
MUNIZED AGAINST SOLUBILIZED
HEPATOMA-SPECIFIC ANTIGENS.
M. R. PRICE, D. HANNANT, J. G. BOWEN &
R. W. BALDWIN, Cancer Research Campaign
Laboratories, University of Nottingham
Currently available evidence strongly favours
the view that immunization with solubilized
tumour-specific antigens from the aminoazo
dye-induced rat hepatoma D23 preferentially
induces suppressor lymphoid cells. Similar
cells are also demonstrable in the thymus of
hepatoma-bearing rats, since these cells have
the capacity to abrogate tumour-specific
transplant-rejection immunity in immune
rats. This effect has been reproduced with the
soluble fraction of lysates of thymus cells
from rats treated with soluble 3M KCI ex-
tracts of tumour, indicating the involvement
ofa tumour-specific soluble suppressor factor.
In order to interrupt the maturation of pre-
cursor suppressor lymphoid cells, rats were
treated with cyclophosphamide (40 mg/kg)
before immunization with soluble hepatoma
D23 antigen preparations. Animals receiving
such treatment were subsequently found to
be protected against s.c. challenge with
viable tumour cells, a response which has
formerly not been achieved with acellular rat
hepatoma-specific antigens.
CONCANAVALIN -A -INDUCED SUP-
PRESSOR ACTIVITY OF LYMPHO-
CYTES DERIVED FROM HODGKIN'S
DISEASE SPLEENS. A. AKBAR, D. B.
JONES, S. V. PAYNE AND D. H. WRIGHT,
University Department of Pathology, General
Hospital, Southampton
Marked changes in lymphocyte subpopula-
tions occur in the spleen in Hodgkin's disease
before histological evidence of lymphoma
involvement, and have been implicated in the
pathogenesis of the condition (Payne et al.,
1976, Clin. Exp. Immunol., 24, 280).
We report results from a preliminary study of
concanavalin-A (Con-A)-inducible non-speci-
fie suppressor cells present in lymphocytes
extracted from spleen tissues. T- and B-
enrichedlymphocyte suspensions from spleens
taken at Hodgkin's staging laparotomy are
optimally stimulated with Con-A for 24 h,
washed thoroughly in the presence of x-
methyl manopyranoside and then mixed at a
1: 3 ratio with normal allogeneic peripheral-
blood responder cells stimulated with Poke-
weed mitogen (PWM). Immunoglobulin pro-
duction at 7 days is measured by immuno-
fluorescence on acetone-fixed cytocentrifuge
preparations. Control cultures consist of
splenic lymphocytes pre-cultured without
Con-A and responder cells cultured alone.
In 4 HD spleens, Con-A-prestimulated T-
enriched lymphocyte preparations (range 81-
9200 sheep-rosetting cells) gave 40-60% 0
suppression of PWM-induced immuno-
globulin production relative to control pre-
stimulated cells (P<001). Two B-enriched
preparations (70 and 76% surface Jg+ cells)
failed to suppress under identical conditions.
The requirements for suppressor induction in
spleen are different from those for peripheral
blood lymphocytes. Whilst these preliminary
data are insufficient to enable comment on
alterations in suppressor-cell function in HD,
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we present the results as a viable technique
for the measurement ofthis T-cell function in
lymphocytes extracted from malignant and
pre-malignant tissue.
AUTOREACTIVE LYMPHOCYTES IN
COLONIC CARCINOMA. B. M. VOSE*,
M. MOORE*, P. GALLAGHERt & P. F.
SCHOFIELDt, *Department of Immunology,
Patterson Laboratories and tDepartment of
Surgery, Withington Hospital, Manchester
The cytotoxicity of lymphocytes from blood,
mesenteric lymph node and tumour have been
tested for cytotoxicity against autologous
colon tumour cells. A short term (4 h) 5ICr-
release assay was used. Significant cytotoxic
reactivity was recorded in 15/23 cases, with
most of the positive reactions occurring in
Dukes' Stages B and C. Blood lymphocytes
from 2/15 healthy individuals were also
reactive. In Stage B blood lymphocytes were
cytotoxic more frequently than node lympho-
cytes. Nodes distant from the tumour in-
duced damage in only 1/10 cases, whereas
those within 2 cm of the neoplasm were posi-
tive in 4/13 patients. In Stage C reactivity in
blood and proximal and distal mesenteric
lymph nodes occurred together. When pre-
sent, cytotoxicity could be concentrated in
cells rosetting with sheep erythrocytes or by
filtration through nylon-fibre columns.
Lymphocytes isolated from 6 tumours
showed killing of neither autologous tumour
nor the K562 cell line, even in cases where
effectors from other sites were reactive. Con-
centration of tumour-infiltrating T cells by
passage through nylon columns did not induce
cytotoxicity. Autoreactive cytolytic lympho-
cytes can thus be detected in colonic neo-
plasia. The association of these with the
clinical course of disease and prognosis is
currently under investigation.
THE INTESTINAL CYTOTOXIC CELL
RESPONSE TO AN i.p. INOCULATED
ALLOGENEIC TUMOUR. M. D. J.
DAVIES & D. M. V. PARROTT, Dept of Bac-
teriology and Immunology, Western Infirmary,
Glasgow
Responses to i.p. inoculated tumours in
organized lymphoid tissues and the peri-
toneal cavity are well documented. Mucosal
surfaces, which frequently contain many
lymphocytes, have received less attention.
Using a new preparation technique, it has
now been possible to examine lymphoid cells
of the lamina propria of murine small in-
testine. 5 days after i.p. injection of P-815
tumour cells into C57BL mice, there is a very
high level of specific cytotoxic T cells in the
lamina propria, which cannot be explained by
contamination by Peyer's patch cells. At this
time, the specific cytotoxic T-cell levels in
other organs are at very low levels. The
lamina propria cytotoxic cell levels remain
high, while those throughout the lymphoid
system increase. A pertinent question is
whether this phenomenon is similar to the
preferential localization of intestinally acti-
vated lymphocytes in the intestine rather
than in peripheral sites.
CHARACTERIZATION OF MACRO-
PHAGE SUB-POPULATIONS WITHIN
AN IMMUNOGENIC MURINE FIBRO-
SARCOMA. K. MOORE & W. H. MCBRIDE,
Department ofBacteriology, Edinburgh Univer-
sity Medical School
Peritoneal-exudate macrophages can be frac-
tionated by velocity sedimentation at unit
gravity into sub-populations differing in
their states of activation as determined by
FC-receptor avidity in the binding of IgG-
sensitized erythrocytes, to form EA rosettes.
Activation was associated with macrophages
sedimenting at 5-9 mm/h, whilst those
sedimenting at 1-5 mm/h were less activated
and contained a higher proportion of per-
oxidase-positive cells.
The sedimentation profile of EA-rosette-
forming cells within cell suspensions prepared
from the immunogenic fibrosarcoma FSA-R
was identical to the profile of peritoneal-
exudate cells, and isolation of tumour-
infiltrating macrophages indicated at least 2
sub-populations.
Comparison of tumour macrophages with
peritoneal macrophages indicates that the
highly activated, rapidly sedimenting fraction
is in the same state of activation as corres-
ponding Corynebacterium parvum-activated
macrophages, and both are more highly
activated than proteose/peptone-elicited
macrophages. The less rapidly sedimenting
tumour-macrophage fraction was more highly
activated than the corresponding C. parvum
fraction, which was in turn more activated
than proteose/peptone-elicited macrophages.
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Thus the macrophage component of the
host-cell infiltrate within a solid tumour is a
heterogeneous population composed of differ-
ent stages ofdifferentiation.
IMMUNOPEROXIDASE STAINING OF
AN ANTI - NCA - FREE ANTI - CEA
IMMUNOGLOBULIN WITH LUNG
TUMOURS ONLY AFTER TRYPSIN-
IZATION. C. H. J. FORD, A. J. SALTER &
C. E. NEWMAN, Clinical Oncology Unit,
University of Birmingham, Queen Elizabeth
Hospital, Birmingham
An absorbed anti-CEA Ig (donated by
IDRL, University of Birmingham), shown to
localize in vivo (Dykes etal., 1980, Br. Med. J.,
i, 220) has been further absorbed with a
glutaraldehyde-fixed polymer of normal
human spleen to remove anti-NCA anti-
bodies. Immunoperoxidase (Heyderman &
Neville, 1977, J. Clin. Pathol., 30, 138) was
used to investigate cellular localization after
absorption. Chronic myeloid leukaemia cells
or sections of formalin-fixed spleen were used
as targets, as they express NCA. After
absorption, the Ig still contained a high titre
of anti-CEA antibodies in an enzyme-linked
immunosorbent assay. However, by immuno-
peroxidase it failed to stain a lung tumour
previously known to localize anti-CEA anti-
bodies, and showed only weak, restricted
staining of liver metastases containing CEA,
or a breast or colon tumour, all of which had
been strongly positive before absorption.
Only after treatment of sections with 0-100
trypsin for 2 h was it possible to demonstrate
tumour-cell staining in sections from 15/27
lung-cancer patients. Of 11 patients who had
raised serum CEA levels (> 40 ng/ml) pre-
operatively, 9 were positive; of 10 who de-
veloped raised levels postoperatively, 4 were
positive; of 6 who had normal levels through-
out follow-up, 2 were positive. Although an
absorbed non-immune sheep Ig did not stain
tumour cells after 2h trypsinization, both
this, and the absorbed anti-CEA Ig, showed
considerable staining of collagen. As little is
known of the effect of trypsin on antigenic
determinants in tissue sections, these pre-
liminary results must be treated with
caution. However, they illustrate the prob-
lems of working with a highly absorbed anti-
CEA Ig, and raise the possibility that some
reports of anti-CEA localization in vitro in
lung tumours may be due to specific anti-
NCA antibodies, or antibodies directed at
antigenic determinants common to both
CEA and NCA.
LIMITED SPECIFICITY OF AN ANTI-
LUNG TUMOUR ANTISERUM IN A
FUSED-ROCKET IMMUNOELECTRO-
PHORESIS (FRIEP) TECHNIQUE. C. S.
WOODHOUSE, C. H. J. FORD & C. E. NEWMAN,
Clinical Oncology Unit, University ofBirming-
ham, Queen Elizabeth Hospital, Birmingham
An antiserum raised to a cultured human
small-(oat-)cell carcinoma line (OCCI) (Ford
& Newman, 1979, Carcino-Embryonic Pro-
teins, 2, 541) w%as investigated using FRIEP.
Extracts prepared from normal lung and lung
tumour tissues were used as a reference panel
against which antibody specificity could be
judged, by comparison with the pattern pro-
duced by "monospecific" antisera. The un-
absorbed antiserum showed relatively high
titre reactivity against no more than 4 anti-
gens in any one extract and produced no pre-
cipitates against human serum in crossed-
immunoelectrophoresis.
Using this antiserum, an antigen has been
demonstrated in a saline extract of a
squamous-cell lung carcinoma from the panel
of extracts. The antigen is not detectable by
FRIEP in extracts of normal lung adjacent
to the tumour, of a second squamous-cell
carcinoma nor of several normal lung tissues.
Comparison wTith antisera to 25 serum pro-
teins (CEA, AFP, Ferritin, retinol-binding
protein, HCG af unit, SPI, PAG or tumour-
associated antigens described by Veltri
(Veltri et al., 1977, Cancer Res., 37, 1313),
Irie (Irie et al., 1976, Cancer Res., 39, 2902)
and Gennings (Gennings et al., 1979, Carcino-
Embryonic Proteins, 2, 553) has failed to
identify the antigen. It is soluble in 50%/-
saturated ammonium sulphate and shows an
OZ2 electrophoretic mobility in agarose at pH
8 6. The presence of this antigen in extracts
of several other lung tuinours is now being
examined.
The ability to identify the uniqueness of
this antigen by the unabsorbed antiserum and
its limited reactivity are notable, since xeno-
antisera raised to tumour cells characteristic-
ally require extensive absorption before
selectivity can be shown.
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IN VITRO CYTOTOXICITY OF AN
ANTI-CEAIMMUNOGLOBULINWITH
CULTURED LUNG TUMOUR CELLS.
J. R. JOHNSON, C. E. NEWMAN & C. H. J.
FORD, Clinical Oncology Unit, University of
Birmingham, Queen Elizabeth Hospital, Birm-
ingham
A high-titre anti-CEA Ig, supplied by the
Immunodiagnostic Research Laboratory
(IDRL), University of Birmingham, has pre-
viously been shown to localize on human
tumours in vivo (Dykes et al., 1980, Br. Med.
J., i, 220). Using indirect immunofluorescent
and immunoperoxidase techniques, the same
Ig shows surface and cytoplasmic localization
with cells from a human anaplastic lung-
tumour line (Calu-6). A temporal variation
exists with the proportion of cells staining in
the immunofluorescence test, being highest in
the lag phase ofculture growth and decreasing
during the log phase.
In a 51Cr-release assay, the same Ig is cyto-
toxic to Calu-6 target cells used immediately
after trypsinization, when 20% of cells
show localization of the Ig. This effect is
augmented by the addition of rabbit comple-
ment, but abolished by priorheat inactivation
of the Ig (56°C, 30 min).
Although vincristine exhibits no immediate
lysis, in the presence of heat-inactivated Ig
or heat-inactivated Ig and complement its
cytotoxicity is greatly increased and appar-
ently dose-dependent. Similar effects with
adriamycin, 5-fluorouracil, bleomycin and
methotrexate have not been obtained.
The specificity ofthese interactions is under
investigation.
BIOLOGICAL ACTIVITY OF MONO-
CLONAL ANTIBODY TO A SPON-
TANEOUS RAT MAMMARY CARCIN-
OMA. M. J. EMBLETON, J. G. MIDDLE &
G. R. FLANNERY, Cancer Research Campaign
Laboratories, University of Nottingham
A tumour-specific monoclonal antibody was
prepared against a rat mammary carcinoma,
Sp4, by the production and cloning of a
hybrid between mouse myeloma cells (P3-
NS1) and spleen cells from an Sp4-immune
rat. This antibody was detected by 1251 anti-
globulin binding, and further studies have
been undertaken to determine its activity in
tumour transplantation in vivo, and in
complement-dependent and cell-dependent
cytotoxicity tests in vitro. These studies are
aimed at evaluating the therapeutic potential
of monoclonal antibodies to tumour cells.
ARYL AZIDES AS RADIOSENSITIZ-
ING AGENTS: A PRELIMINARY
PHOTO-CHEMICAL EVALUATION.
M. F. G. STEVENS & C. K. WONG, Cancer
Chemotherapy Research Group, Department of
Pharmacy, University ofAston in Birmingham
Aryl azides undergo photolytic and radiolytic
degradation to transient reactive species
(arylnitrenes) capable ofversatile interactions
with biological substrates (Knowles, 1972,
Accounts Chem. Res., 5, 155). The effects of 4
azides [9-(3-azidoanilino)acridine (1), 9-(4-
azidoanilino)acridine (2), 9-(4-azido-2-meth-
oxyanilino)acridine (3) and 4-azidobenzene-
sulphonamide (4)] on L-1210 cells in RPMI
medium were examined in the dark and dur-
ing exposure to light (366 nm) for 5 min. Cell
numbers were measured with a Coulter
Counter and cytotoxicity was expressed as
ID80 (jug/ml); each result is a mean of three
determinations.
Cytotoxicity ofazides
to L-1210 cells
k
Compound: ID80 (dark)
(1) 61
(2) 11
(3) 1 1
(4) >Ix 103
ID80 (light)
5-5
0 9
4,3
Results indicated that irradiation enhanced
cytotoxicity of the drugs in all cases, but the
most dramatic effect was elicited by the
azidosulphonamide (4) which was non-cyto-
toxic in the dark bu significantly cytotoxic
when incubated with L-1210 cells in light.
Pre-irradiation of the azidosulphonamide
solution before exposure to L-1210 cells
abolished activity (IDgo> 1 x 103 [g). In
control experiments the stable photoproducts
formed from azidosulphonamide were found
to be non-cytotoxic, and it is possible that a
photogenerated nitrene species is the de-
structive agent.
EFFECTS OF DEXAMETHASONE ON
THE PHARMACOKINETICS AND
TOXICITY OF MISONIDAZOLE IN
MICE. P. WORKMAN, MRC Clinical Oncology
and Radiotherapeutics Unit, Cambridge
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Previous studies (Workman, 1979, Br. J.
Cancer, 40, 335) have shown that pretreat-
ment of mice with phenobarbitone or pheny-
toin increased the acute LD50 of the hypoxic
cell radiosensitizer misonidazole (Ro 07-0582;
MISO). The mechanism involves an increased
rate of metabolism to desmethylmisonidazole
(Ro 05-9963; DEMISO) through induction of
hepatic microsomal enzymes, which decreases
the area under the curve (AUC) for MISO in
blood and brain. Clinical studies are in pro-
gress to assess the possible role of plieno-
barbitone and phenytoin, and also the cortico-
steroid dexamethasone, in reducing MISO
neurotoxicity.
Experiments were carried out to investigate
the interaction between dexamethasone
sodium phosphate (DEX) and MISO in C3H
mice. MISO was injected i.p. at a dose of
1 g/kg and MISO and DEMISO w-ere meas-
ured in blood and brain by high-performance
liquid chromatography (Workman et al.,
1978, J. Chromatogr., 147, 507). Pretreatment
with DEX (0.5, 25 and 100 mg/kg i.p. daily
for 5 days) had no effect on the metabolism,
pharmacokinetics and urinary excretion of
MISO. Simultaneously administered DEX
(25 mg/kg i.v.) did not alter the blood con-
centrations of MISO and DE1MISO, but did
reduce the brain MISO AUC by 1500
(P<0-02).
Simultaneous DEX did not change the
acute LD50 for MISO (1 -1 9 g/kg). However,
this was reduced to 1-7 g/kg after pretreat-
ment with 0-5 mg/kg/day DEX, and decreased
further at the higher doses of DEX.
DRUG INTERACTIONS WITH MISON-
IDAZOLE IN THE DOG. R. A. S. WHITE,
Dept. Clin. Vet. Medicine, and P. WORKMAN,
Clinical Oncology and Radiotherapeutics,
Cambridge
The hypoxic cell radiosensitizing drug mison-
idazole (MISO) is currently being evaluated
in several clinical trials, but its total dose has
been found to be limited by neurotoxic side-
effects. We have investigated in the dog the
interactions of several drugs likely to be used
in combination with MISO which may alter
its pharmacokinetic behaviour and possibly
its efficacy and toxicity.
Cyclophosphamide (Cy 50 mg/mi2 every
2nd day for 9 wks) was found to delay oral
absorption and reduce peak plasma MISO
concentrations by 3000, but bioavailability
was generally unimpaired. Half-life was ex-
tended by up to 350 in 1 dog.
Phenytoin sodium (15 mg/kg daily pretreat-
ment for 10 days) peak plasma concentra-
tions were reduced by 10%, plasma half-life
by 400/ and total tissue exposure by 3500.
Pretreatment with phenobarbitone achieved
a similar effect, although simultaneous
sodium pentobarbitone increased peaks by
1000 and tissue exposure by 30%o.
Dexamethasone (0-1 mg/kg daily for 9
weeks) was found to have no effect on
MISO pharmacokinetics.
RESPONSE TO CHEMOTHERAPY OF
MULTICELLULAR TUMOUR SPHER-
OIDS IN STATIC CULTURE P. R.
TWENTYMAN, MRC Clinical Oncology and
Radiotherapeutics Units, Hills Road, Cam-
bridge
Multicellular tumour spheroids of several cell
lines have been grown using a static culture
technique modified from that of Yuhas et al.
(1977, Cancer Res., 37, 3639). These lines in-
clude the EMT6 and RIF-1 mouse tumours
and the HT29 and CaMa-1 human colon and
breast carcinomas. Response of the growing
spheroids to cytotoxic drug treatment in
vitro has been studied using both spheroid
growth delay and clonogenic cell survival as
endpoints. In EMT6 spheroids, time of assay
after drug treatment was an important para-
meter in the determination of cell survival.
Apparent recovery from potentially lethal
damage occurred after treatment with nitro-
gen mustard (NH2), BCNU, CCNU, myleran
and cis-platinum. For this group of agents a
reasonably similar relationship was found
between spheroid growth delay and cell
survival (measured 24 h after treatment). For
adriamycin, actinomycin D and 5 fluorourcil,
however, extended grow%th delay was ob-
served w%ith relatively little cell kill. The
human cell spheroids were similar to EMT6
in sensitivity to HN2 (as assayed by growth
delay) but markedly less sensitive to BCNU.
The relationship betwreen spheroid growtth
delay and cell survival in RIF-1 and HT29
spheroids is currently being investigated.
Many features of the tumour spheroid
model system make it amenable to the in-
vestigation of tumour-response parameters in
a wvay that cannot be done with simpler
monolayer cultures.
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STUDIES WITH HYPERTHERMIA
AND CYTOTOXIC DRUGS USING
EMT6 MULTICELLULAR TUMOUR
SPHEROIDS. J. E. MORGAN & N. M.
BLEEHEN, MRC Clinical Oncology and Radio-
therapeutics Unit, Cambridge
Multicellular tumour spheroids show many
characteristics of in vivo tumours which are
not present in monolayer cultures. In these
studies spheroids of the EMT6/Ca/VJAC cell
line have been used as a relatively sophisti-
cated in vitro model system to investigate
interactions between hyperthermia and sonle
commonly used cytotoxic agents. Heating
was carried out by total immersion in a
thermostatically controlled circulating water-
bath. The response of the spheroids to treat-
ment has been assayed, both in terms of
growth delay and of surviving fraction after
trypsinization. Using spheroids 200-300 Km
in diameter we have demonstrated a signifi-
cant enhancement of bleomycin cytotoxicity
at 43°C. For example, a growth delay of 0 40
days seen after exposure to 10 ,ug/ml BLM
for 1 h at 37°C is increased to 3 05 days at
43°C. Heat alone under these conditions pro-
duces a growth delay of0 50 days. Preheating
at 40°C has previously been shown to alter the
response to EMT6 cells to subsequent heat
and drug exposures. Similarly with spheroids,
a prior exposure of 6 h at 40°C induces
tolerance to subsequent BLM (20 ,ug/ml) at
43°C/1 h, reducing the growth delay from
5-95 days to 3 70 days. With adriamycin, no
increased cytotoxicity was seen after a lh
exposure at 43°C. However, prolonged ex-
posure (6 h) to 1 ,ug/ml adriamycin increased
the growth delay from 1-10 days at 37°C to
4-15 days at 42°C. Current investigations into
the heat and drug sensitivities of spheroids
pretreated with 5mM MISO at 37°C under
both oxic and hypoxic conditions were also
reported.
EFFECT OF HIGH BLOOD-SUGAR
LEVELS ON BLOOD FLOW AND
THERMAL RESPONSES OF ANIMAL
TUMOURS. S. K. CALDERWOOD & J. A.
DICKSON, Cancer Research Unit, Dept of
Clinical Biochemistry, Royal Victoria In-
firmary, Newcastle upon Tyne
There is now considerable evidence that
several types of animal and human tumours
are damaged by heating at temperatures
>42°C, while normal tissues are unaffected.
The current work concerns approaches where-
by this heating effect may be potentiated.
Blood flow in the Yoshida sarcoma (meas-
sured by rubidium-86) was inhibited by 90-
10000 at high blood-glucose levels (>20mM).
A similar finding was obtained in MC-7
sarcoma and D-23 carcinoma. The inhibition
in each tumour was independent of site,
occurring in s.c. tumours on the foot and
flank and in i.m. leg tumours, and was similar
at a range of tumour volumes. A similar in-
hibition was produced by galactose, a sugar
not metabolized by the tumours. In the i.m.
VX2 carcinoma in the rabbit, blood flow was
also inhibited by hyperglycaemia. Blood flow
in normal tissues of the animals was little
affected by hyperglycaemia.
The inhibition of blood flow enhanced the
specificity of thermotherapy; the tumour was
unable to dissipate heat via circulatory blood,
whilst normal tissues were cooled by a heat-
induced increase in blood flow which was
unaltered by the increase in blood sugar.
Tumour heating was more uniform at high
sugar levels and the use of such conditions,
combined with heat, may eliminate the inci-
dence of "cool zones" around tumour blood
vessels.
If inhibition of blood flow at high blood-
sugar level proves a general phenomenon in
tumours, it may represent an Achilles' heel
for selective therapy in cancer cells isolated
from the host.
CIRCULATING IMMUNE COM-
PLEXES IN DOGS WITH OSTEO-
SARCOMA. A. SEGAL-EIRAS, R. A. ROBINS,
L. OWENS & R. W. BALDWIN. Cancer Re-
search Laboratories, University of Nottingham
It is known that some dog malignant diseases
present similar characteristics to those found
in humans (Ankerst et al., 1973, Bull. W.H.O.,
49, 205). The present study shows the results
from the 1251-Clq binding assay in an
attempt to analyse circulating immune com-
plexes (CIC) in dogs bearing osteogenic
sarcoma (OS). Serum and plasma samples
from adult large dogs with OS, normal Irish
wolfhounds and beagles were tested for CIC
by the Clq-binding test. A high proportion
(36/43; 83o%) of the OS sera showed high
Clq-binding levels. These results were com-
pared with those obtained in normal dog
samples, where Clq values were low. The
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Clq-binding technique has been slightly
modified in this laboratory by the use of
heparin (Baldwin et al., 1979, Behring Inst.
mitt., 64, 63) which increases the discrimina-
tion between normal and pathological samples
in the study on human tumours. Correlative
determination of Clq-binding levels in serum
and heparinized plasma showed that the
addition of heparin increased Clq binding
in normal dog samples with a smaller increase
in Clq binding withplasma samplesfrom dogs
with OS. The investigations on dogs' sera
revealed a very clear-cut difference of Clq-
binding levels between the tumour-bearing
animals and the normal, without any addition
of heparin. Five dogs with OS were studied
for CIC when samples were taken before and
after treatment. Post-therapy serum samples
showed a decrease of Clq-binding levels in
all cases, and so far these dogs remain without
clinical evidence of disease. It is tempting to
consider that the Clq-binding test may be
a useful method of studying CIC in dogs
with osteogenic sarcoma.
CIRCULATING IMMUNE COM-
PLEXES IN HUMAN BONE NEO-
PLASIA. A. SEGAL-EIRAS, R. A. ROBINS,
R. W. BALDWIN & V. S. BYERS, Cancer
Research Laboratories, University of Notting-
ham
Serum samples from patients bearing osteo-
genic sarcoma (OS), giant cell tumour (GCT),
osteoblastoma and healthy controls were
studied for the presence of circulating im-
mune complexes (CIC) by the 125J-Clq-
binding assay, slightly modified by the in-
clusion of heparin (Baldwin et al., 1979,
Behring Inst. Mitt., 64, 63). A high proportion
(42/62; 67-7%) of the OS sera showed high
Clq binding. Similarly, 1251-Clq-binding
assay with sera from GCT patients revealed
t high proportion with elevated Clq binding
levels. These results were compared with
those obtained with sera from patients with
benign osteoblastoma, and with 20 sera from
normal young donors. In the benign bone-
tumour group none of the sera tested showed
high Clq binding, and of the normal young
donors samples, only 1 serum gave a signifi-
cantly high Clq binding. Serum samples from
2 patients were available for limited study of
sequential changes in serum Clq binding. In
one patient, high Clq binding was seen pre-
operatively and in the immediate post-
operative period, with values subsequently
decreasing, remaining in the normal range for
4 years; this patient continues free of clinical
evidence of disease. In a second patient, Clq
binding returned to normal for only a brief
period after amputation, followed by con-
sistently high Clq binding; this patient died
of metastic disease. There is some suggestive
evidence that some of the Clq binding is due
to tumour-related CIC. A finding of note in
the present studies is the elevation of CIC in
OS, but none in benign osteoblastoma or
normal young donors; similar results were
obtained using the heparin-modified Clq-
binding assay for comparing breast carcinoma
with benign breast diseases.
DETECTION OF IMMUNE COM-
PLEXES IN SERA FROM PATIENTS
WITH CHRONIC LUNG DISEASES,
USING THE Clq-BINDING ASSAY
K. M. COOPER, M. MOORE & A. M. HILTON,
Paterson Laboratories, Christie Hospital, Man-
chester
Levels of Clq-binding activity (Clq BA) in
the sera of patient with various chronic lung
diseases and healthy controls, were measured
by the technique of Zubler & Lambert (1976,
J. Immunol., 116, 232) under conditions
where (i) the limit of detection of human
aggregated IgG was 5 Hug (absolute amount)
and (ii) there was freedom from interference
by DNA and LPS. Clq BA for 50 controls
gave an upper limit of 4-500o (mean+2 s.d.)
levels above which in patients' sera were con-
sidered positive. Four main groups ofpatients
were studied, whose Clq BA status was as
follows.
Ca bronchus
Bronchiectasis
Chronic
bronchitis
Asthma
No. pos./
No. tested
(0)
33/60 (55)
19/29 (66)
ClqBA mean + s.d.
(range)
9-77+ 14-23 (1-53-78-40)
9-33 + 7-31 (1-60-24-05)
7/37 (19) 3-49+ 2-12 (1-64-12-16)
4/22 (18) 3-20 + 1-24 (1-90-5-94)
There was no correlation between Clq BA
and serum levels of C-reactive protein, C3,
C4, or IgM among the patients with Ca
bronchus and bronchiectasis. However, there
was a positive correlation with IgA and IgG
levels. The data indicate that Clq BA in sera
is associated with both degenerative and
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neoplastic conditions of the lung. It is sug-
gested that Clq BA in these diseases may be
a reflection of an autoimmune response to
antigens released during the course of tissue
degeneration/proliferation.
IN VITRO REACTION OF CANCER
PATIENTS AND OTHERS TO BCG.
A. J. COCHRAN*, G. TODDt, C. W. CHAN§,
R. D. KENNEDYt, R. MACKIE+ & L. MOR-
RISONt, *Surgical Oncology, UCLA,tWestern
Infirmary, Glasgowand §Queen Mary Hospital,
Hong Kong
Recall-antigen skin testing is useful for
assessing immune competence. However,
serial monitoring of cancer patients is im-
practical because of interpretative problems
from reimmunization by repeated antigen
exposure. We investigated in vitro BCG
reactivity in 68 cancer patients and 121
controls (disease-free or with non-debilitating,
non-malignant conditions) from a highly
tuberculin-sensitized population. A one-stage
capillary leucocyte (blood) migration inhibi-
tion assay was used. "Antigen" was Glaxo
BCG at 25, 37 5, 50, 75 and 100 ug/ml. The
reaction frequency of cancer and control
groups increased with increasing BCG con-
centration, but patients were always less
reactive than controls. Maximum separation
was at 37-5 and 50 ,tg/ml of BCG. Cancer
patients' reactivity declined significantly
wA-ith advancing disease. Stage I patients Mwere
similarly reactive whether or not tumour was
present. Stage II patients wvith tumour pre-
sent wvere less frequently reactive (4/12) than
those with tumour (8/12). A small decline in
reactivity occurred in controls over 60 years
old. The in vitro test correlated well with
the Mantoux test; 8/11 controls gave con-
current concordant results. In cancer patients
from a highly tuberculin-reactive population
and in BCG recipients, this simple assay per-
formed serially may aid the prediction of
metastases.
IMMUNOCYTOCHEMICAL LOCALIZ-
ATION OF OESTROGEN RECEPTORS
J. HUMPHREYS*, J. H. WESTWOODt, M. G.
ORMERODt, R. C. COOMBES* & A. M.
NEVILLE* (Introduced by G. C. Easty),
*Ludwig Institute for Cancer Research and
tInstitute for Cancer Research, Sutton, Surrey
The main purpose of the immunocyto-
chemical localization of oestrogen receptors
(ER) is to replace a cumbersome radio-
chemical assay with a simple histological
technique. We have extensively evaluated 3
methods: (1) Conjugation of oestradiol (E2)
to immunoglobulin G (IgG) or horseradish
peroxidase (HRPO). IgG-conjugated E2 was
applied to a tissue section in a similar manner
to the first antibody in an immunoenzymatic
technique. An antiserum raised against
E2IgG, and conjugated with HRPO, was
then applied to frozen sections of ER-rich
tissues (including breast carcinomas), as in an
immunoperoxidase protocol. Staining was
obtained, but further studies are necessary to
determine its specificity. Alternatively, con-
jugation of E2 directly to HRPO eliminated
the second step, but produced a less encour-
aging result. (2) A triple sandw-ich" tech-
nique using anti-oestradiol serum. In this
method ER is localized by applying E2, anti-
E2 and HRPO-linked second antibody in
sequence. Early results wvere positive, but
iionspecific staining could not be excluded,
since the first antiserum may have contained
unwanted antibodies. (3) Immunofluorescence
using fluoroscein isothiocyanate (FITC)-con-
jugated E2. Two methods, after Pertschuk
et al. (1979, Am. J. Clin. Pathol., 71, 504) and
Lee (1979, Cancer, 44, 1) were followed in an
attempt to detect ER by immunofluores-
cence. E2 w%vas linked to FITC via bovine
serum albumen. With Pertschuk's method,
fluorescence in ER+ tissues was obtained
routinely, but we could find no evidence that
this was specific. A conjugate made after Lee
had very poor binding ability to ER on assay.
We conclude that immunocytochemical tech-
niques as currently used produce results that
should be interpreted most cautiously. This
may be due to the unstable and very soluble
nature of the ER molecule, and studies are
under way to overcome these factors.
DETECTIONOFMICROMETASTASES
OF MAMMARY CARCINOMA USING
AN IMMUNOHISTOCHEMICAL
STAIN FOREPITHELIAL MEMBRANE
ANTIGEN (EMA). M. G. ORMEROD*, J. P.
SLOANEt, S. F. IMRIE*, K. STEELE*, R. C.
COOMBES+ & A. M. NEVILLEt, *Institute for
Cancer Research, Royal Cancer Hospital,
tRoyal Marsden Hospital, tLudwig Institute
for Cancer Research, Royal Marsden Hospital,
Sutton, Surrey
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The human epithelial membrane antigen
(EMA) has been found on the surface or
luminal membranes of most non-squamous
epithelium (Heyderman et al., 1979, J. Clin.
Pathol., 32, 35). All lymphoid tissues were
negative. The antigen is produced by most
carcinomas.
In mammary carcinomas, any lumina
formed invariably stained for EMA. In many
tumours it was also found in the cytoplasm,
particularly in single cells in infiltrates or
metastases. An immunohistochemical stain
for EMA has been used in sections of fixed
tissues to detect micrometastases which
could not be recognized by conventional
histology.
We have stained sections of aspirates of
marrowv from patients with metastatic mam-
mary carcinoma. 10% of the aspirates which
had been read as negative on an H.±E. sec-
tion were shown to contain metastatic cells.
IDENTIFICATION OF DIFFERENT
CELL TYPES USING TWO ENZYME
REACTIONS MEASURED SIMUL-
TANEOUSLY IN SINGLE CELLS WITH
A MULTI-PARAMETER FLOW CYTO-
METER. S. H. CHAMBERS & J. V. WATSON,
MRC Clinical Oncology Unit, The Medical
School, Cambridge
A prerequisite for the eventual use of flow
cytometers in clinical medicine is the ability
to distinguish reliably between the different
cell types that are always present in any
biopsy sample. It would also be advantageous
to be able to obtain sorted functionally active
cells for further manipulations. Most staining
procedures, apart from vital DNA staining
with benzimidazole derivatives, surface-mar-
ker labelling and those using fluorescein
diacetate (FDA) result in cell death. By
assaying simultaneously with the fluorogenic
esterase substrates 4-methylumbelliferyl
acetate (MUA) and FDA it has been possible
to distinguish between a number of different
cell types. Furthermore, in 2 tumour-cell
lines in which plating experiments have been
carried out, the cloning ability has been
retained at above 9000 for MUA and FDA
exposures ofup to 6 h. Both these compounds
are hydrolysed nonspecifically by esterases;
thus at least two enzymes may be present in
each cell type, each with different specificities
and reaction-rate characteristics for these
substrates.
PHYSICO-BIOCHEMICAL PROPER-
TIES OF SUBPOPULATIONS IN
MOUSE MARROW. J. V. WATSON & S. H.
CHAMBERS, MRC Clinical Oncology Unit, The
Medical School, Cambridge
Preliminary studies have been conducted on
mouse marrow with a multiparameter flow
cytometer. Blue light scattered from un-
stained cells in the foward direction (40-8°)
and measured simultaneously with that scat-
tered at right angles (855-93°) from each cell
revealed 4 distinct, possibly 5 clusters.
Similar 2-dimensional studies with UV light
showed at least 6 different clusters. Twin
enzyme reactions measured simultaneously
with 4-methylumbelliferone acetate (UV
excitation, violet analysis) and fluorescein
diacetate (blue excitation, green analysis)
have showAn at least 8 different populations
with their different reaction-rate characteris-
tics. Although some populations are likely to
be common to each pair of the 3 assay
modalities it is likely that some are not. The
combined assay using all 6 parameters
simultaneously has not yet been made, but
we hope it will be possible to identify marrow
stem cells within this 6-dimensional assay
space and to cell sort for positive functional
identification after the instrument has been
upgraded.
A TWIN LASER MULTI-PARAMETER
ANALYSING FLOW CYTOMETER. J. V.
WATSON, MRC Clinical Oncology Unit, The
Medical School, Cambridge
Most laser-based flow cytometers lack fluores-
cence excitation versatility, due to the limited
number of lasing lines that can be obtained
with a single laser. Even with a large tunable
laser only one wavelength can be obtained at
a time, which considerably reduced the poten-
tial ofsuch instruments. These problems have
been overcome in our unit by the design and
construction of a flow cytometer with a small
argon laser emitting blue light at 488 nm,
which is used in conjunction w-ith a large
krypton laser. The latter can be tuned to
emit in the UV, violet, green, yellow or red
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and any one of these lines can be used for
excitation either sequentially or simul-
taneously w%%ith the blue line from the argon
laser. Narrow-angle forward light scatter at
two wavelengths, plus 900 light collection and
analysis in the UV, violet/low blue, high blue,
green and red wavelength bands can be
achieved simultaneously givsing 7-parameter
analysis. The principles of operation, design
specifications and preliminary performance
data wAere described.
MEASUREMENT OF LECTIN BIND-
ING TO HUMAN MYELOID AND
LYMPHOID CELLS USING FLOW
CYTOMETRY. G. BLACKLEDGE, J. GALLAG-
HER, A. MORRIS & D. CROWTHER, CRC
Department of Medical Oncology, Manchester
University and Christie Hospital, Manchester
Lectins are proteins, derived mainly from
plant tissues, which bind reversibly to mono-
saccharides of defined configuration and
structure. In the oligosaccharide chains of
glycoproteins, lectins recognize principally,
but not exclusively, sugar residues at non-
reducing termini. Using flow cytometry we
have investigated the binding of3 fluorescent-
conjugated lectins (ConA, WGA, LCA) to
the surface membrane of a human erythro-
leukaemia cell line, K562. By this method it
was found that incubation of cells with lectin
at 4°C (to prevent endocytosis) for 30 min
gave maximal binding and reproducible
measurement of surface fluorescence. Speci-
ficity of binding was measured by incubation
with appropriate sugar inhibitors (of methyl
mannoside for ConA and LCA and N-acetyl
glucosamine for WGA) and 50-80°, of the
lectin fluorescence was abolished under these
conditions. Dialysed serum which contains
glycoproteins was also an effective inhibitor
of lectin binding. Using unlabelled lectins,
competition studies of lectin binding were
carried out. Although LCA and ConA bind
to similar sugars, unlabelled ConA at high
concentrations could only inhibit 7000 of the
FITC-LCA binding. This suggests the exist-
ence of high-affinity sites for LCA on the
surface of K562 cells.
Differences in lectin binding have beeni seen
between different human cell types. Lympho-
cytes and lymphoma cells have fewer binding
sites for ConA on their surface than myeloid
and myeloid leukaemia cells. Cells from
chronic lymphocytic leukaemia have fewer
binding sites for ConA than normal lympho-
cytes. Lectin binding may prove of clinical
relevance as a prognostic factor in the
lymphomas.
CELL KINETICS OF PERTURBA-
TIONS OF SKIN, MARROW AND
TUMOUR CELLS INDUCED BY HIGH-
DOSE INFUSION OF HYDROXYUREA
IN PATIENTS WITH BREAST CAN-
CER. M. LAMBERT & H. BUSH, CRC Depart-
ment of Medical Oncology, Christie Hospital
and Holt Radium Institute, Manchester
Four patients with advanced breast cancer
were treated with a 72h continuous infusion
hydroxyurea (HU) at 6-12 g/day. Biopsy
specimens of marrow, skin and tumour were
taken before the infusion was begun and
again at 72, 78 and 84 h. The [3H]-TdR-
labelling index (LI) of these specimens was
determined by the method of Meyer & Bauer
(1975) with ARG for 10 days, and in addition
the S-phase proportion of the marrow was
determined by flow cytofluorimetry after
nuclear staining with propidium iodide. In
patients in whom adequate serum levels of
HU were sustained (>01mM), the LI of the
marrow was reduced by the infusion from a
pretreatment level of 7-15% (mean 12%) to
2-6% (mean 4.50/) at 72 h. After the infusion
wNas discontinued a rebound phenomenon was
seen with a marrow LI at 78 h of 12-25%
(mean 20%) and at 84 h of 15-22°o (mean
1850 ). Similar values for the S-phase propor-
tion were obtained by cytofluorimetry. The
pretreatment LI of the skin specimens was
1 0-255% (mean 1 60°) and at 72 h it was
reduced to 0-2-0-6% (mean 040o) and again
a rebound was seen at 78 h (LI 2-5-14%,
mean 6.2%) and at 84 h (LI 15-22%, mean
180/). The tumour specimens, however,
showAed little perturbation, the pretreatment
LI was 4-7-160/o (mean 10%), at 72 h 9-1600
(mean 12%), and at 78 h 9-220/ (mean 15%).
Attempts at preferential in vivo synchrony of
normal human tumour cell populations have
been partially successful. The biological and
technical problems associated w%rith this tech-
nique will be discussed. This and similar
techniques (Ara-C infusion) offers the possi-
bilitv of selective protection of dividing skin,
marrow, and gut cell populations in cancer
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patients treated with cytotoxic drugs and
radiotherapy.
SOMATIC CELL HYBRIDIZATION
STUDIES ON THE NATURE OF CEL-
LULAR RESISTANCE TO ICRF 159
(RAZOXANE). D. H. EDGAR & A. M.
CREIGILTON, CellularPharmacology Laboratory,
Imperial Cancer Research Fund, London
Two sublines of BHK 21S cells with inde-
pendently induced resistance to ICRF 159
have been fused with drug-sensitive lines and
the drug responses of the resultant somatic
cell hybrids have been characterized. Fusion
of either of the resistant lines with drug-
sensitive Syrian hamster cells yields intra-
specific hybrids which demonstrate inter-
mediate levels of drug resistance in colony-
forming assays. Since resistance is not due to
impaired uptake of ICRF 159 (White &
Creighton, 1976, Br. J. Cancer, 34, 323) this
result suggests that these resistant lines have
either high levels of a drug-specific target or a
target with decreased drug susceptibility.
The characteristic perturbation of cell-
cycle distribution which results when ICRF
159 is present in a cell population has been
investigated in sensitive, resistant and hybrid
cells treated with the drug. We have found in
the lines examined an inverse correlation
between the degree of perturbation caused by
a single dose of ICRF 159 and the resistance
index ofthe cell line, as determined by colony-
forming assays. In this system therefore flow
cytofluorimetry can be used to give an early
indication of response to ICRF 159.
CYCLOSPORIN A IN TUMOUR-BEAR-
ING RODENTS. S. E. HECKFORD, S. A.
ECCLES & P. ALEXANDER, Division ofTumour
Immunclogy, Institute of Cancer Research,
Sutton, Surrey
Cyclosporin A (Sandoz Ltd) is a new immuno-
suppressive agent with little myelotoxicity,
which is being used to replace corticosteroid
treatment in kidney-transplant patients and
to suppress GVH disease in marrow-graft
recipients. In view of the current interest in
Cyclosporin A (CYA) we are investigating its
effects on the biology of a variety of rodent
tumours.
CYA will allow allograft tumours to grow
progressively, but in the syngeneic host it has
no detectable effect on the biological charac-
teristics of the primary tumour implant. If
CYA is administered during the growth of
fibrosarcomas in mice or rats, the incidence
of metastases following tumour resection is
significantly greater than in control groups.
We are currently investigating the effect of
CYA on rechallenge immunity, as we have
found that administration of CYA after
excision of the primary tumour implants also
facilitates the growth ofdisseminated tumour
cells. In contrast, CYA does not appear to
alter the incidence of metastases in animals
that have borne skin or mammary carcin-
omas.
MACROPHAGES AND METASTATIC
POTENTIAL IN MOUSE MAMMARY
TUMOURS. J. R. G. NASH, J. E. PRICE &
D. TARIN, Department of Histopathology, John
Radcliffe Hospital, University of Oxford
Individual tumours contain different propor-
tions of non-neoplastic cells. Some of these
are stromal, whilst others possibly have a
protective function, mediated immunologic-
ally or otherwise. It has previously been re-
ported that transplantable tumours of high
metastatic potential contain fewer macro-
phages than ones incapable of dissemination.
However, the processes of tumour trans-
plantation and of maintaining tumours in
culture probably alter their properties, and
we have therefore chosen to re-examine the
relationship ofmacrophage content to tumour
spread, using primary mammary tumours in
mice.
Ingestion of latex particles proved too non-
specific for reliably identifying macrophages
in tumour-cell suspensions, and histochemical
staining for enzymes such as lysosome, acid
phosphatase and nonspecific esterase proved
even more limited in value. We therefore used
the Fe-mediated phagocytosis assay, in
which antibody-coated sheep red cells are
ingested by the macrophages under controlled
conditions, to quantitate tumour macrophage
content expressed as a proportion of total
cells in the tumour suspension. With this we
found moderate variation between tumours,
both in the proportion of macrophages and
in their phagocytic capacity.
The metastatic colonization potential of
the tumours was assayed by necropsy of mice
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90 days after i.v. inoculation of the dis-
aggregated tumour cells, and the results for
individual tumours was correlated with their
macrophage content at the time of inocula-
tion. It was found that there is no correlation
between macrophage content and the colon-
ization potential of these primary tumours.
EFFECT OF INHIBITION OF PLATE-
LET FUNCTION ON SEEDING OF
CIRCULATING TUMOUR CELLS. N.
WILLMOTT, A. BAXTER & K. C. CALMAN,
Department of Clinical Oncology, University of
Glasgow, and A. MALCOLM, Department of
Pathology, Western Infirmary, Glasgow
The accretion of platelets has been postu-
lated to facilitate the seeding of metastatic
tumour cells. To test whether this hypothesis
applied to the TLX-5 murine lymphoma, the
occurrence of blood-borne metastases was
mimicked by injecting a low number (1-5
x 102) of TLX-5 lymphoma cells i.v. Tumour
spread was not confined to the first vascular
bed encountered, the lungs, but was also
evident in liver, kidney and spleen. An
attempt to prevent the seeding of injected
lymphoma cells was made by injecting an
inhibitor of platelet function, RA233 (30 mg/
kg) i.v. 3 min before the lymphoma cells.
This procedure had no effect on the survival
time of tumour-bearing mice, which were all
dead within 12 days regardless of treatment.
In separate experiments it was shown that
RA 233 could inhibit platelet function. Thus,
the drop in circulating platelet count caused
by Corynebacterium parvum injected i.v.
could be prevented if RA233 (30 mg/kg) was
injected i.v. 3 min earlier. That is to say,
although prior treatment with RA233 could
prevent the platelet aggregation caused by
C. parvum, it did not affect survival time
when injected before tumour cells. It is there-
fore concluded that platelet accretion is not
necessary for the seeding of i.v. injected
TLX-5 lymphoma cells.
LEWIS LUNG CARCINOMA: SELECT-
ING METASTATIC VARIANTS. M.
MAGUDIA, P. WHUR, J. LoCKWOOD, J.
BOSTON & D. C. WILLIAMS, Marie Curie
Memorial Foundation, Oxted, Surrey
A stable line of Lewis lung carcinoma was
maintained in mice by i.m. passage of cells
from pooled primary tumours. Various para-
meters were monitored: (1) Latent period.
(2) Growth rate. (3) Number of lung meta-
stases. (4) Differential cell counts of primary
tumours and metastases.
To obtain a high-metastasis variant the
procedure was repeated substituting cells
from lung tumours. The latent and the
growth periodsincreased witheachgeneration,
and by the second passage differed signifi-
cantly from those of the control group, in-
dicating a slower primary tumour growth
rate with each successive generation. The
number and size of metastases increased after
the first passage (75 + 10 compared to 55 + 1
for stable line (P<0 01)). In both lines
primary tumours contained more tumour
cells and less macrophages than metastases,
but the high-metastasis varient contained
fewer macrophages at both sites than the
stable line. This suggests a lowered immune
response to the variant.
Low-metastasis variants were obtained by
adapting cells to monolayer culture. Only a
few tumour cells survived to form established
cultures, and these were reinjected into mice.
The latent and the growth periods increased
substantially, and there were fewer meta-
stases in the lungs. However, cells of meta-
static origin produced significantly more
metastases (22 + 4) than primary cells (9 + 4)
(P <0 05).
These findings indicatethat cells with vary-
ing metastatic potentials exist within pri-
mary tumour cell populations. Cells of high
metastatic variants can be isolated by appro-
priate experimental procedures.
METASTATIC COLONIZATION PO-
TENTIAL OF PRIMARY TUMOURS
INOCULATED BY DIFFERENT
ROUTES. D. TARIN & J. E. PRICE, Depart-
ment of Histopathology, John Radcliffe Hos-
pital, University of Oxford
In previous studies on primary mammary
tumours we found that cells from some could
heavily colonize the lungs after i.v. inocula-
tion in mice, whereas those from others did
so weakly or not at all. The tumours were all
adenocarcinomas and we could find no
features which correlated with this be-
havioural variation. However, the high re-
producibility of the findings in each batch of
animals inoculated with a given tumour
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indicated that the differences between indi-
vidual tumours were due to intrinsic differ-
ences in their constituent cells.
To see whether interplay between these
intrinsic properties and local env-ironmental
factors in organs containing tumour cells
affects colony formation, we inoculated cells
from each of 23 primary mammary tumours
by 4 different routes. The routes chosen wi-ere
via the tail vein or the hepatic portal vein or
s.c. or i.p., and for each wre used a separate
batch of mice. The animals were killed and
necropsied at 90 days and the distribution of
deposits recorded.
In this experiment, comprising over 250
animals, it was found that, first, tumours
which consistently colonized by one route of
inoculation did not necessarily do so by all
route.s and, secondly, the combination of
orgains in wlhich the inoculated tumour cells
grew varied from tumour to tuinour. These
observations indicate that failure or success
in colonization of the lungs after i.v. inocula-
tion is not simply a matter of tumour trans-
plantability, and is determined by interplay
between intrinsic properties of the tumour
cells themselves and local host influences in
the sites where they lodge.
A TECHNIQUE FOR THE STUDY OF
LYMPHOCYTE RECIRCULATION IN
HUMANS USING INDIUM'll LABEL-
LING. J. WAGSTAFF, C. GIBSON, N.
THATCHER, WV. L. FORD* & D. CROWTHER,
CRC Department of Medical Oncology,
Christie Hospital, and *the Medical School,
Manchester University, Manchester
Indium"ll oxine has been shown to be an
efficient label for lymphocytes (Rannie et al.,
1977, Clin. Exp. Immunol., 29, 509). It allows
external gamma imaging (Frost et al., 1979,
Int. J. Nucl. Med. Biol., 6, 60) not possible
with chromium. Only one report (Lavender
et al., 1977, Br. Med. J., ii, 797) has been pub-
lished applying this technique to humans. We
have labelled lymphocytes obtained from
peripheral blood using the Haemonetics Cell
Separator. Lymphocyte migration from the
blood to the liver, lungs, spleen and lymph
nodes was followed using surface-probe
counting, gamma-camera imaging and blood
sampling. Normal volunteers and patients
with chronic lymphocytic leukaemia, lymph-
oma and solid tumours have been studied.
Preliminary results show imaging of spleen
and lymph nodes. Blood curves in normals
are similar to results previously reported
using chromium (Jonsson & Christensen,
1978, Scand. J. Haematol., 20, 319). In
clhronic lymphocytic leukaemia and lymph-
oma, two patient groups have been dis-
tinguished, one with slower-than-normal
blood clearances as previously reported
(Bremer et al., 1978, Lymphology, 2, 231) and
the second faster. LTsing dynamic gamma-
camera imaging, new information on the
early kinetics of reinjected lymplhocytes has
been obtained. Data showing activity changes
with time in various organs (heart, lung, liver
and spleen) have been obtained with the help
ofcomputer storage and analysis. These tech-
niques allow the study of lymphocyte re-
circulation in humans by non-invasive means.
TREATMENT OFLOCALIZED MALIG-
NANT LYMPHOMA OF THE ORBIT.
G. THOAIAS (introduced by Dr P. M. Wilkin-
son), Department of Clinical Pharmacology,
Christie Hospital, Mlianchester
Twenty-three patients (mean age 61-range
5-87) with histologically proven orbital
lymphoma received treatment during the
period 1946-1975. Because of the long period,
detailed evaluation was not possible in all
cases, but clinically all patients had localized
disease with normal peripheral-blood count
and clhest X-rays. The median duration of
follow up is 126 months (range 44-318). Nine
patients are alive with no further evidence of
disease, one patient had a relapse successfully
treated at 100 months, 10 patients died of
incidental causes. 2 wA,ere lost to follow up (at
120 and 136 months) and in one patient it
wNas impossible to determine the cause of
death. The ratio of observed/expected deaths
was 0-66. Altlhough this particular site is said
to carry a poor prognosis it wzNould appearthat,
in patients with localized disease, treatment
with radiotherapy alone is satisfactory.
IMPROVED RESULTS OF TREAT-
MENT OF GASTROINTESTINAL
LYMPHOMA BY COMBINED-MODA-
LITY THERAPY. G. BLACKLEDGE & D.
CROWTHER, CRC Department of Medical
Oncology, Christie Hospital, Mlanche.ster
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Thirty-two patients with gastrointestinal
lymphoma have been treated at this hospital
between 1976 and 1979, 12 with disease
arising in the stomach, 16 with disease in the
small intestine and 4 with large intestinal
disease. Nine of the patients had nodular
histologies, 12 had diffuse poorly differenti-
ated lymphocytic or undifferentiated histo-
logy and 11 had diffuse histiocytic lymphoma
(DHL). The patients were staged using the
classification proposed by us (Blackledge et
al., 1979, Clin. Oncol., 5, 209). This has
allowed a comparison ofsurvival with a retro-
spective study of 104 patients, allowing for
similar stage. Combination chemotherapy,
vincristine, adriamycin and prednisone for
DPDL and DHL, and cyclophosphamide,
vincristine and prednisone for the nodular
lymphomas, was given to patients with Stage
II or greater disease (30/32), followed by
radiotherapy to the abdomen whenever
possible. Nineteen patients (530/,) achieved a
complete remission. Actuarial survival curves
showed 510 alive at 3 vears, with the deaths
occurring within the first year. Improvements
in survival were seen in Stage IIB/c, 9000/
2-year survival compared with 3000 in the
retrospective study, and Stage III, 550/0
2-year survival compared w,ith 20% in the
previous study (P=0 0079). Patients wAith
DHL had a survival of 630" at 2 years, with
no deaths after 4 months. Patients with local
problems, e.g. perforation or malabsorption,
during treatment had median survival of 8
months, compared with 61% of patients
without these problems being alive at 3 years.
Combined-modality treatment with com-
bination chemotherapy and radiotherapy
represents an advance in the management of
gastroiintestinal lymphloma.
EXTRAMEDULLARY PLASMACYT-
OMAS. A. L. PAHOR*, J. A. H. WATER-
HOUSEt & J. POWELLt, *E.N.T. Department,
Dudley Road and Sandwell D.G. Hospitals,
Birmingham, tRegional CancerRegistry, Birm-
ingham
Extramedullary plasmacytomas (EMP) are
uncommon tumours. Their diagnosis presents
difficulty for 1oth the clinician and the
pathologist. They can be solitary or multiple.
Thirty-three cases were diagnosed in the
Birmingham Region between 1963 and 1976
(24 solitary and 9 multiple). The commonst
site is the head and neck (24). Three cases
have primary lymphonode involvement. This
series is one of the largest reported in the
literature so far and is population-based, thus
reflecting the true incidence more than
hospital-based series. Conditions which can
be mistaken for EMP are chronic nonspecific
infections such as plasma-cell polyp of the
vocal cord; chronic specific infections such as
yaws and sarcoidosis; monomorphic tumours
such as neuroblastoma, reticulosarcoma and
lymphomas. Investigations to exclude mul-
tiple myeloma are essential and should be
carried out from the onset. A scoring system
is designed to monitor the transformation of
EMP to multiple myeloma and thus be a
guide to chemotherapeutic treatment. Treat-
ment of EMP is essentially radiotherapy.
Life-long follow-up is mandatory in all cases,
as local or distant recurrences can occur many
years after apparently successful treatment.
EMP should be considered as premyeloma
stage and we urge the formation of a multi-
disciplinary group to study EMP, which hope-
fully will lead to more understanding of
multiple myeloma.
PRIMARY LYMPHOMAS OF THE
TESTIS. G. READ, The Christie Hospital and
Holt Radium Institute, Manchester
Primary lymphoma of the testis is rare.
During the period 1960-1979, 1307 patients
with testicular tumours were registered at
the Christie Hospital and Holt Radium
Institute. Ofthese, only 51 patients were con-
sidered to have a primary lymphoma of the
testis, the pathology being either the diffuse
histiocytic, poorly differentiated lympho-
cytic or undifferentiated histological type.
There were no cases of Hodgkin's disease of
the testis. Only in those patients in whom the
testicular involvement was the presenting
symptom or the dominant feature was the
testis accepted as the primary site. Eight
cases had bilateral testicular involvement,
and in 23 patients the disease was apparently
confined to the testicle at presentation. The
patients were treated in most instances by
radiotherapy, though in later years chemo-
therapy was also used. The results of treat-
ment are presented. Survival was poor. In the
28 patients with evidence of metastases at
presentation, only 3 lived more than 12
months. However, the .5-year age-corrected
189BACR MEETING
survival in the patients with disease confined
to the testicle, was 30%0. Bone, skin and liver
involvement was especially common. There is
insufficient experience yet to determine
whether chemotherapy has improved the
outcome.
THE PROGNOSTIC SIGNIFICANCE
OF SERUM p2-MICROGLOBULIN IN
MULTIPLE MYELOMA. D. NORFOLK,
J. A. CHILD, S. KERRUISH, E. H. COOPER &
A. M. WARD, The Department ofHaematology,
The General Infirmary at Leeds, The Unit for
Cancer Research, University of Leeds and The
Supra Regional Protein Reference Laboratory,
Sheffield
The levels of serum 32-microglobulin (:2-m)
were measured serially in 36 patients with
multiple myeloma for 6 moniths to 5 years.
The initial :2-m levels are highly correlated
to survival (P=0 01). The median survival in
months, according to the initial ,82-m levels
(number of patients in parentheses) -was as
follows: >6 mg/l, 14 months (11); 3-6 mg/I,
19 months (12) and <3 mg/l, >50 months
(13). These levels of :2-m are correlated to
tumour mass as calculated from multifac-
torial indices. An initial :2-m of >3 mg/l
tended to fall on treatment but rarely reached
normal, a rising value usually heralded an
irreversible progression, and when > 8 mg/l,
often accompanied by renal failure. The level
of < 3 mg/l was usually associated with a
relatively benign evolution but carried an
increased risk of infection.
These detailed studies have been compared
to the pattern in 120 patients analysed by the
Protein Reference Laboratory, and indicate
they are representative of the disease in
general. Creatinine > 140 nM was only present
in 3 ofthe patients in the longitudinal studies
and in 10% of the Sheffield series. The para-
protein levels show a far wider variation than
those Of ,82-m
ALLOGENEIC MARROW TRANS-
PLANTATION IN ACUTE MYELOID
LEUKAEMIA-AN UPDATE OF THE
ROYAL MARSDEN HOSPITAL
SERIES. D. W. HEDLEY, Royal Marsden
Hospital Bone Marrow Transplant Team,
Sutton, Surrey
Although conventional drug treatment pro-
duces a remission rate of around 70%0, virtu-
ally all patients with acute myeloid leukaemic
(AML) relapse and ultimately die of their
disease. More radical treatment while in re-
mission with total body irradiation (TBI) and
allogeneic marrow transplantation (BMT)
from a histocompatible sibling donor now
appears to offer the prospect of permanent
cure (Thomas et al., 1977, Blood, 49, 511) and
of 29 patients in first remission of AML
treated in this manner at the Royal Marsden
Hospital (RMH) only 3 have so far relapsed.
Furthermore, the early part of the survival
curve for these patients is no worse than that
ofa similar series ofnon-grafted patients (who
did not have a matched sibling donor), sug-
gesting that TBI and BMT are not associated
with an excess of early, treatment-related
deaths.
The use of the newr immunosuppressive
agent Cyclosporin A has reduced the inci-
dence offatal GVH disease from 11/26 to 1/25
in the RMH series, and we are now exploring
the use of partially mis-matched donors.
TBI and BMT should be considered for
patients with AML in remis,sion who have
histocompatible siblings.
THE ROLE OF TRANSTRACHEAL
ASPIRATION IN THE DIAGNOSIS OF
RESPIRATORY INFECTION IN NEU-
TROPENIC PATIENTS WITH ACUTE
LEUKAEMIA. M. L. SLEVIN, R. BELL,
A. G. CATTO-SMITH, E. J. SHAW, J. M. FORD,
J. S. MALPAS & T. A. LISTER, ICRF Depart-
ment of Medical Oncology and Department of
Bacteriology, St Bartholomew's Hospital, Lon-
don
Transtracheal aspiration (TTA) was per-
formed during 35 febrile episodes in 31
neutropenic patients with acute leukaemic
and clinical or radiological evidence of res-
piratory-tract infection. Twenty-five patients
were receiving antibiotics at the time of TTA
(Tobramycin and Cephazolin 14, Tobra-
mycin and Flucloxacillin 5, other combina-
tions 6). A 14-gauge Davol IVI catheter was
inserted under sterile conditions through the
crico-thyroid membrane. Bronchial secre-
tions were aspirated, with or without lavage
with 10 ml of normal saline, and specimens
were cultured immediately. The procedure
was carried out under platelet cover if indi-
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cated, and no serious haemorrhagic complica-
tions were seen. Minor surgical emphysema
occurred in one patient. There was no radio-
logical evidence of pneumothorax. Positive
cultures w,%ere obtained from TTAs (46%). In
these 16 cases, concurrent sputum examina-
tion was positive to culture in only 4, nega-
tive in 5, and unobtainable in 7. There was no
case in which the TTA was negative and the
sputum positive. The TTA was positive in
16/30 cases in which the chest radiograph was
abnormal. 12 cases in whom the TTA was
positive were receiving broad-spectrum anti-
biotics and in 8 of these the regimen was
altered. In the 4 positive cases not an anti-
biotics, the findings influenced the choice of
drugs. The high diagnostic yield of this
simple test suggests that its routine use in the
diagnosis of chest infection in neutropenic
patients should be further evaluated.
NEUTROPENIA AND INFECTION IN
ACUTE MYELOGENOUS LEUK-
AEMIA. A COMPARISON OF THREE
CHEMOTHERAPEUTIC REGIMENS.
A. ROHATINER, R. BELL, J. FORD, J. S.
MALPAS & T. A. LISTER, ICRF Department of
Medical Oncology, St Bartholomew's Hospital,
London
The relationship of fatal infection to neutro-
penia during remission induction for AML is
analysed. 150 consecutive patients received
repeated cycles of Adriamycin (ADR) Cyto-
sine Arabinoside (Ara-C), Vincristine and
Prednisolone given over 9 days (Regimen 1),
or ADR, Ara-C and Thioguanine given over
5 days, at either high (Regimen 2) or very
high doses (Regimen 3). The table shows the
number of pts and fatal infections and the
mean duration of neutropenia in days, asso-
ciated with the first 2 treatment cycles, when
all the infective deaths occurred.
Regi-
men
1
2
3
Pts
82
27
41
Fatal
infec
tions
19
1:3
Neutrophils x 109/1
<0 1 0-1-05 05- 10
23
19
19
12
10
8
5
5.4
The duration of neutropenia was longest in
Regimen 1 (possibly because treatment was
given over 9 days) and was virtually identical
in Regimens 2 and 3. However, there was a
significantly higher incidence offatal infection
13
in the more intensively treated group (Regi-
men 2 vs 3, P<005). 22/34 fatal infections
were preceded by profound neutropenia
(neutrophils <041 x 10q/l) for a mean of 8
days. 27 of these 34 pts showed no rise in
neutrophil count in response to infection. The
data confirm that fatal infections are asso-
ciated with persistant severe neutropenia.
Initensification of therapy, resulting in a sig-
nificant increase in fatal infections, did not
increase the degree or duration of neutro-
penia, suggesting that other factors, such as
mucosal ulceration significantly contribute to
outcome.
CYTOGENETIC EVIDENCE FOR A
NEW CLONE AT RELAPSE OF ALL:
A CASE REPORT. L. M. SECKER-WALKER
& C. A. SIEFF, Dept of Cytogenetics and Im-
munology, Royal Marsden Hospital, Fulham
Road, and Dept of Haematology, Hospital for
Sick Children, Great Ormond Street
Two possible mechanisms of disease relapse
in acute lymphoblastic leukaemia (ALL) have
been suggested. Cells of the malignant clone,
harboured since diagnosis, may re-emerge;
alternatively leukaemia may occur in a pre-
viously unaffected cell-line. A case is reported
in which chromosomal evidence, from each of
three disease episodes, indicates the working
of both mechanisms at different times in the
same patient.
A boy aged 7 years when ALL was diag-
nosed, had a first marrow relapse 4 years
later. This was followed by a good second
remission of 18 months. The patient died in
second relapse 6 years after diganosis. On
marrow morphology and cytochemistry the
cells in the 3 disease episodes were indis-
tinguishable. The chromosome constitution
of all marrow cells at diagnosis was 47 XX,
del(5)(q13)del(15)(q15)+Mar. However, both
relapses were associated with a new chromo-
somally abnormal clone characterized by a
long-arm deletion ofchromosome 6, with none
of the abnormalities seen at diagnosis. The
use of chromosomal abnormalities to identify
a malignant clone is considered in the light of
tumour-evolution theory. The influence of
therapy on the suppression, eradication and/
or initiation of a chromosomally abnormal
malignant clone is discussed.
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THERAPEUTIC DRUG MONITORING
OF METHOTREXATE. J. F. B. STUART,
J. G. MCVIE & K. C. CALMAN, Department of
Clinical Oncology, and J. R. LAWRENCE &
W. H. STEELE, Department ofMateria Medica,
University of Glasgow
High-dose MTX in the treatment of osteo-
genie sarcomas requires monitoring of MTX
throughout the infusion and up to at least
48 h afterwards, in order to establish the
amount of folinic acid required to avoid
toxicity. Enzyme immunological techniques
in the form of the "EMIT" system (Syva)
provide a rapid method of analysis. Com-
parability with other methods of analysis is
important to establish the serum concentra-
tions of the MTX at which folinic acid is
administered. Preliminary results in 30
samples show that readings using selenium-
based radioimmunoassay (RIA) (Paxton et
al., 1978, Clin. Chem., 24, 1534) were about
67% of results using the EMIT system. This
difference between the assays was found over
the whole concentration range: RIA 66% at
0-1000 nM; 62% at 1000-5000 nm and 730o
in samples containing > 5000 nm. Overall
there was good correlation between the
methods (r=0-84, P<0-001).
METABOLISM AND EXCRETION OF
METHOTREXATE (MTX) IN MAN.
A. L. STEWART, J. MARGISON & P. M.
WILKINSON, Department of Clinical Pharma-
cology, Christie Hospital, Manchester
Previous kinetic studies of MTX have relied
on drug determination principally by 3H-
MTX which is now known to present certain
technical difficulties and makes identification
of metabolites difficult. We have developed
an unambiguous HPLC assay for both MTX
and 7,OH-MTX and compared concentra-
tions ofboth in bile, serum and urine to those
obtained by radioimmunoassay (RIA). Two
patients with choledocal T-tubes received
MTX 100 mg/mi2 i.v.; both patients had
disseminated malignancy, but renal and
hepatic function were normal by conventional
biochemical criteria. The decay of drug in
serum was triphasic, and concentrations were
similar for both assavs, with the exception of
the terminal decay phase. For urine, although
RIA in these 2 patients gave similar concen-
trations to HPLC, it has consistently over-
estimated drug excretion in a larger patient
series, due to interference from 2 4-diamino
N10-methylpteroic acid. It was not possible
to determine MTX accurately in bile by RIA
because of marked quenching. It was, how-
ever, readily identifiable by HPLC, peak
concentrations being reached 0 5-3 h after
drug administration. Decay of drug in bile
was biphasic, with a mean terminal half-life
of 15 h. The biliary concentration always
exceeded that in serum, with a maximum
bile:serum ratio of 100:1. Cumulative biliary
excretion could only be determined in one
patient, where 13% of the administered dose
was excreted in 48 h. Although moderate-dose
MTX is said not to be metabolized, 7,OH-
MTX was identified in all 3 constituents. Only
small amounts were present in bile in con-
trast to serum where substantial amounts
may be present 24 h after administration.
This study confirms that the renal route is the
main excretory pathway for MTX, and on the
basis of these observations dose reduction is
probably not necessary in the presence of
obstructive jaundice.
PHARMACOKINETICS OF CYCLO-
PHOSPHAMIDE IN PATIENTS WITH
OAT-CELL CARCINOMA OF THE
BRONCHUS. P. M. WILKINSON, N.
THATCHER, S. B. LUCAS & S. CUSHING, Dept
Clinical Pharmacology and CRC Dept of
Medical Oncology, Christie Hospital, Man-
chester
Serial serum and urine concentrations of
cyclophosphamide (CY) and alkylating met-
abolites (AM) were determined in 8 patients
with histologically proven oat-cell carcinoma
of the bronchus following i.v. doses of 1.5,
2-5 and 3.5 g/m2 respectively. For eaclh dose
the serum decay was triphasic, the mean
terminal half-life of CY being 5 8, 8 6 and 8 8
h and of AM 14, 14 7 and 12-6 h. Although
considerable variation between patients was
observed in the AM/CY ratio, this did not
increase with successive dose increments. The
area under the concentration/time curve from
6-24 h for CY could be directly correlated
with the percentage fall in neutrophil count,
but for the AM this applied to the terminal
phase only. No significant difference was
found between the change in neutrophil
count and response but there was one
between ratios and response. We conclude
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that incremental dose increase does not im-
pair hepatic biotransformation of CY, and
that the AM/CY ratio may be an important
factor in predicting tumour response.
BLEOMYCIN DRUG MONITORING IN
THE MANAGEMENT OF MALIGNANT
EFFUSIONS. J. F. B. STUART, J. M.
TROTTER, J. G. MCVIE & K. C. CALMAN,
Department of Clinical Oncology, University of
Glasgow, and W. AHERNE & S. JAMES, Depart-
ment of Biochemistry, University ofSurrey
Intracavitary bleomycin (BLM) has now been
used in a total of 35 patients with malignant
effusions, with an overall response rate of
7000. There were 6 possible drug-related
deaths with this therapy; apart from this it
was well tolerated, with low toxicity. Trotter
et al. (1979, Br. J. Cancer, 40, 310) have
shown that high serum levels of BLM in one
of the treatment-related deaths suggests that
intracavitary doses of BLM in excess of
40 mg/M2 should be avoided in the elderly.
These findings led to BLM monitoring in
all patients given the drug by the intrapleural
or i.p. routes. Systemic peak concentrations
of BLM showed a 5- to 10-fold increase in
some cases, and one of the patients who died
had normal plasma concentrations of BLM
during a previous infusion with the same dose
schedules. In a further 5 patients studied who
had low toxicity, the systemic BLM concen-
tration was 4000 of that when equivalent
amounts were given by the i.v. route (Stuart
et al., 1979, Br. J. Cancer, 40, 316).
In a further 4 patients a predictive dose of
5 mg BLM was given, followed by the appro-
priate higher dose 4-5 h later. The mechanism
of BLM toxicity associated with these levels
of intracavitary drug is unclear, but it seems
reasonable to continue to monitor BLM
during intracavitary theiapy.
ESTIMATION OF EXPOSURE TO AL-
KYLATING AGENTS USING GAS
CHROMATOGRAPHY - MASS SPEC-
TROMETRY. P. B. FARMER & E. BAILEY,
MRC Toxicology Unit, Carshalton, Surrey
Alkylating agents form an important class of
environmental carcinogens, in addition to
being widelv used as anti-cancer agents. In
vivo exposure to alkylating agents leads to
the formation of 8-alkylcysteine and N-
alkylhistidine derivatives in haemoglobin.
Methods have been developed for the quanti-
tation of these amino acids in rat or human
haemoglobin, using capillary gas chromato-
graphy-chemical ionization--mass spectro-
metry. After treatment of rats with the
methylating agent methyl methanesulphon-
ate (MSS) the amount of S-methylcysteine in
haemoglobin bears a linear relationship with
the dose of MMS injected. In contrast, the
degree of methylation after injection of the
anti-cancer drug 5-(3,3-dimethyl-1-triazene)-
imidazole-4-carboxamide (DTIC) is very low.
Hydroxyethylhistidine has been determined
in the haemoglobin (after sodium boro-
hydride reduction) of humans exposed to
vinyl chloride.
BIOGENESIS OF BLADDER CANCER
IN THE FISCHER 344 RAT BY INTRA-
GASTRIC N-BUTYL-N-(4-HYDROXY-
BUTYL) NITROSAMINE (BBN). R. M.
HICKS, J. CHOWANIEC, E. D. MASSEY & A.
HARVEY, School of Pathology, Middlesex
Hosp. Med. School, London
The biological response of animals to BBN is
affected by species (Hirose et al., 1976, Gann,
67, 175), strain (Moon, unpublished) and sex
(Bertram & Craig, 1972, Eur. J. Cancer, 8,
587). It is an organ-specific bladder carcino-
gen for the rat, and we also find it to be a
powerful bladder carcinogen for the hamster
but ineffective in the baboon (Hicks et al.,
unpublished). In the Fischer 344 rat, BBN
produces multi-focal, large, exophytic, well-
differentiated, transitional-cell tumours with
some squamous metaplasia, which generally
do not metastasize but slowly invade the
bladder wall. Their histopathology and ultra-
structure are comparable to low-grade, super-
ficial, papillary bladder cancers in man which
are often regarded as relatively benign.
Nevertheless the survival of these animals is
related to the BBN dose and the tumours
cause death by obstruction and haemorrhage.
The dose-response to BBN is measured in
terms of total tumour volume produced with
time and is reffected by the life tables. The
BBN/Fischer rat system has been used in
many laboratories to induce bladder tumours
for chemotherapeutic trials and other investi-
gations. Its suitability as a model for human
bladder cancer is limited to the local disease
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only, and it cannot be used to study meta-
stasis.
SILICA-INDUCED LYMPHOMA
RATS. M. M. FENNELL WAGNER &
WAGNER, MRC Pneumoconiosis Unit,
dough Hospital, Penarth, S. Glamorgan
IN
J. C.
Llan-
Following upon a single i.p. injection of
crystalline silica (quartz) into the pleural
cavity of Wistar-derived rats at 5-6 weeks of
age, malignant lymphomas develop (Wagner,
J. C., 1962, Natare, 196, 180). They have been
designated malignant lymphoma of histio-
cytic type (Wagner, 1976, J. Natl CancerInst.,
57, 509) and the rate is 40%. In 2 other
strains of rats the rate was 5 and 7 0
(Wagner, submitted for publication) and it
also varied with the type of silica injected
(Wagner, submitted for publication). The
tumours were not found after injection with
saline, coal or carbon (Wagner, 1976).
Lymphocytic lymphosarcoma occurred equal-
ly in saline- and silica-injected rats. Electron
microscopy and role of thymectonmy are dis-
cussed, and the importance of the production
of a lymphoma consequent upon the intro-
duction of an agent believed to be specifically
cytotoxic to macrophages (Allison, 1976, In
Vitro Methods in Cell-Mediated Tumour
Inmunity, p. 395). Although numerous ex-
periments have been performed with quartz
during the last 50 years, this is the only study
in which this mineral has been shown to be
associated with malignancy.
DETECTION OF BBN - INDUCED
BLADDER TUMOURS BY MEASURE-
MENT OF HAEMATURIA AND URINE
CYTOLOGY. J. TURTON, C. HAWKEY*, J.
GWYNNE, L. SIMON & R. M. HICKS, School of
Pathology, Middlesex Hospital Medical School,
and *Nuffield Labs. of Comp. Med., Regent's
Park, London
The development of bladder tumours in the
urinary bladder of the F344 rat in response
to BBN is dose-related. Thus 12 months after
dosing with 300, 600 or 1200 mg BBN the
total tumour volumes were 7,380 and 2200
mm3 respectively. To avoidkilling animals in
order to detect the tumours histologically,
the possibility was investigated of measuring
urine parameters as indicators of tumour
growth. Haematuria was found to parallel
tumour growth. The correlation between
tumour size and haematuria was demon-
strated for individual animals after different
doses of BBN and the sensitivity of the
method discussed. In general, the method is
reliable for the detection of tumours over
40 mm3 in size, but a number of false nega-
tives were obtained with very small tumours.
Haemorrhagic anaemia was found to be asso-
ciated with the presence of large bladder
tumours. Examination of urine sediments of
62 animals by urine cytology gave an 80°/,
correct correlation with bladder pathology as
found at subsequent necropsy. The 6 false
negatives werenotcorrelated withtumour size
but all had heavy fungal contamination pre-
venting accurate diagnosis. Thus while
neither technique alone is entirely reliable,
we have found that together they provide a
useful way of monitoring the progress of
animals in bladder carcinogenesis trials.
CHARACTERISTICS OF N-NITROSO-
METHYLUREA-INDUCED MAMMARY
TUMOURS IN THE RAT. J. C. WILLIAMS,
R. C. COOMBES & B. A. GUSTERSON. (Intro-
duced by G. C. Easty). Ludwig Institute for
Cancer Research, Sutton. Surrey
N-nitrosomethylurea (NMU) has been re-
ported to induce mammary tumours in rats,
with a high incidence ofmetastasis to marrow
and spleen and the development of hyper-
calcaemia (Gullino et al., 1975, J. Natl Cancer
Inst., 54, 401). In our hands i.v. NMU to
50-55-day-old rats induced mammary
tumours in 78% of F344/N and 91% of
ICRF Wistar females. Mean latent period for
F344/N rats was 149 days and for ICRF
Wistar rats was 93 days. 98% of mammary
tumours were classified histologically as
adenocarcinomas. Primary tumours of non-
mammary origin were detected at low inci-
dence. These were squamous-cell carcinomas
in the peri-urethral and auditory regions,
adenocarcinomas of the bronchus, endo-
metrium and colon, primitive neural ecto-
dermal tumours of the brain and dissemi-
nated lymphoma/leukaemia. No histological
evidence was found for metastases of either
the mammary tumours or other primary
tumours in lungs, femora, vertebrae, liver,
kidneys, spleen, brain or adrenals, and plasma
calcium measurements varied within the
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normal range independently of tumour
volume. No histological difference was found
between NMU- and DMBA-induced mam-
mary adenocarcinomas. Oophorectomy at the
time ofNMU administration greatly inhibited
tumour induction; oophorectomy when at
least one tumour per animal was palpable
produced growth delay or regression in all
cases, with subsequent tumour re-growth in
7/8 animals. All NMU- and DMBA-induced
mammary tumours tested contained cyto-
plasmic oestrogein receptor at similar con-
centrations. No evidence for tumour-induced
hypercalcaemia was found. In view of the
inability ofthese tumours to metastasize and/
or cause hypercalcaemia the NMU model of
breast cancer offers little advantage over
other hormonally responsive models.
REACTIVE HYPERPLASIA AFTER
COLOSTOMY CLOSURE ENHANCES
CHEMICAL CARCINOGENESIS IN
THE DISTAL COLON. R. C. N. WILLIAM-
SON, 0. T. TERPSTRA, E. P. DAHL & R. A.
MALT, Massachusetts General Hospital, Boston,
U.S.A., and University Department ofSurgery,
Bristol Royal Infirmary
Adaptive hyperplasia mnay explain enhanced
colonic carcinogenesis in rats after small-
bowel resection (Williamson et al., 1978,
Cancer Res., 38, 3212) or pancreatobiliary
diversion (Williamson et al., 1979, Gastro-
enterology, 76, 1386). Using male Fischer rats
(n=205) susceptibility to cancer was studied
in colon re-exposed to the faecal stream 4
weeks after defunctioning transverse colost-
omy. Other groups had laparotomy alone,
permanent colostomy, or colonic transection
repeated after 4 weeks. Tumours were in-
duced by 1,2-diemthylhydrazine (300 mg/kg)
in divided s.c. doses over 11 weeks, starting
2 days after the second operation.
In distal colon, amounts ofRNA, DNA and
protein fell by 53-5800 4 weeks after trans-
verse colostomy (P<0-001), but returned to
normal within 1 week of colostomy closure.
This reactive hyperplasia promoted the
development of distal tumours, as compared
with repeated colonic transection (incidence
32% vs 60/,: P<0-03). In proximal colon,
protein and nucleic acid contents were un-
altered by transverse colostomy, but were
increased by 18-590 4w,eeks after restoration
of intestinal continuity (P=0 05-0 002);
tumour yields were unchanged, however.
Suture-line tumours were commoner after
repeated transection than after colostomy
closure (760% vs 39 o: P<0-01). The presence
of a permanent colostomy did not affect the
number of distal tumours, but 260/ of these
animals developed cancers at the stoma.
Hypoplasia is confined to the distal colon
after transverse colostomy, but it occurs in
both proximal and distal colon after colost-
omy closure. Intense adaptive hyperplasia
promotes carcinogenesis in the distal colon.
DETECTION OF HERPESVIRUS-
CODED MATERIAL IN NEOPLASTIC
CERVICAL TISSUE. R. P. EGLIN, A. B.
MACLEAN, F. SHARP, J. C. M. MACNAB, J. B.
CLEMENTS & N. M. WILKIE, Departments of
Midwifery and Virology, University of Glasgow
The presence of virus-specific RNA has been
investigated by the technique of in situ
hybridization using 7 5dum sections of human
normal and neoplastic cervical tissue. The
125I-labelled DNA probes used were from
herpes simplex virus 2 (HSV2), adenovirus
types 2 and 5, and bacteriophage A. Results
were assessed by counting grains within a
standard area. A positive result was con-
sidered to be a value at least twice the grain
count for control sections, in at least 2 of the
4 consecutive serial sections on each slide.
No positive hybridization was found for the
adenovirus and bacteriophage probes against
neoplastic and benign cervical tissue. But
HSV2 probe produced positive hybridization
for all 11 biopsies from cervical intraepithelial
neoplasia, for 14/17 squamous-cell cervical
carcinomas, for 1/9 cervical adenocarcinomas,
and 1/10 biopsy samples of benign epi-
thelium. Surface swabs of the cervix taken
from the one case of adenocarcinoma positive
for hybridization were positive for free virus;
all other swabs were negative.
AN INCREASED METHIONINE RE-
QUIREMENT BY TUMOUR CELLS IN
VITRO. M. J. TISDALE, Department of
Biochemistry, St Thomas's Hospital Medical
School, London
The ability of a number of normal and neo-
plastic cell lines to survive and grow in culture
medium in which methionine was replaced by
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its immediate precursor homocysteine has
been studied. None of the tumour lines
showed optimal growth under such nutri-
tional conditions, although there was a
variability in the ability to survive and grow.
In contrast the normal cell lines studied
showed optimal growth in media containing
homocysteine only. Although homocysteine
alone was unable to support growth of
tumour cells, it did stimulate growth under
conditions in which methionine became
growth-limiting. A correlation has been ob-
tained between the ability of a cell line to
survive in media in which homocysteine sub-
stitutes for methionine and the minimal con-
centration ofmethionine required for optimal
growth. Thus normal cell lines grow optimally
in media containing only 05 Htg/ml of methi-
onine in the presence of homocysteine,
whereas some of the tumour cell lines require
a concentration of methionine greater than
2 jtg/ml. This suggests that the inability of
tumour cell lines to survive in methionine-
depleted, homocysteine-supplemented media
is not due to any intrinsic biochemical defect,
but to the higher methionine requirement of
such cells.
CLUSTERING OF STOMACH CANCER
IN ARGYLL, 1971-78. J. McHARDY, C. R.
GILLIS & D. H. HOLE, West ofScotland Cancer
Surveillance Unit, Ruchill Hospital, Glasgow
The establishment of a relationship between
alimentary cancer in cattle and various
putative carcinogens (e.g. bracken, viruses)
and anecdotal evidence of alimentary cancer
in both humans and animals living in close
proximity, suggested an investigation with
implications for human cancer. Consequently
a population-based study of the geographical
distribution of human cancer was carried out
in Argyll in S.W. Scotland where the occur-
rence of bracken is high, and compared with
the distribution of alimentary cancer in
Ayrshire, where bracken is sparse.
Previous studies of human cancer in Ayr-
shire have suggested space/time clustering of
alimentary cancer, and this present study has
revealed a clusterin space andtime ofstomach
cancer which was most marked in the year of
maximum incidence, 1974. This cluster how-
ever did not occur in the same areas as the
alimentary cancer in cattle. Preliminary
studies have been carried out using existing
data of occupation and family background,
trace elements in the soil and nitrates in the
water supply, without yielding definitive
results at this stage.
AN INCREASE IN THE INCIDENCE
OF BLADDER CANCER. C. R. GILLIS*,
W. M. MACINTYRE*, J. M. GLENNIE*, P.
BOYLE*, A. T. SANDISONt & A. J. MALCOLMt,
*West of Scotland Cancer Surveillance Unit,
Ruchill Hospital and tUniversity Dept of
Pathology, Western Infirmary, Glasgow
Clinical study of 667 cases of bladder cancer
seen between 1957 and 1972, together with an
epidemiological study ofbladder cancer in the
County of Ayrshire, Scotland, between 1958
and 1977, revealed a 3-fold increase in inci-
dence. This increase, proportionately similar
in males and females, is not due to changes in
the structure of the population, and an in-
crease of this magnitude has not been re-
ported elsewhere. The cases were classified at
the outset of this clinical study by occupa-
tional status into "'high" and "'low" risk
groups. The high-risk groups consisted of
chemical workers, miners, farm and agricul-
tural workers and rubber workers. While
there was an increase in incidence in the
high-risk group, the most striking increase
occurred in the general population group,
implying the existence of some as yet un-
recognized aetiological factor. The sites
within the bladder at which these tumours
occurred were similar to published series;
however the spectrum of tumour types
differed from other British series in having a
lower representation of transitional-cell
tumours. Whilst these differences may arise
from variations in the evaluation of meta-
plastic change, they may represent a true
variation in bladder-cancer histology.
CANCER OF THE LARYNX IN SCOT-
LAND. P. BOYLE*, A. G. ROBERTSONt, C. R.
GILLIS*, H. YOSEFt & G. E. FLATMANt, *West
of Scotland Cancer Surveillance Unit, Ruchill
Hospital, and tInstitute of Radiotherapeutics
and Oncology, Western Infirmary, Glasgow
Evidence from epidemiological, experimental
and necropsy studies suggests that smoking
cigarettes, cigars or pipes is a significant
causative factor in the development of cancer
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of the larynx. A strong dose-response rela-
tionship with the number ofcigarettes smoked
is a particular feature of the disease. In
Scotland the proportion of the population
smoking remains high, and the average annual
amount oftobacco smoked is increasing. Thus
an increase in mortality from laryngeal cancer
would be expected. However, in Scotland
there has been no increase in mortality from
laryngeal cancer, and neither an increase in
incidence in a well studied area of the West
of Scotland with high-quality registration
data, nor a detectable improvement in sur-
vival to account for this anomaly. Treatment
and staging details were available for patients
treated in the Glasgow Institute of Radio-
therapeutics and Oncology between 1968 and
1978, and the survival was typical of clinical
and registry series over the same period.
CHEMOTHERAPY OF ADVANCED
MALIGNANT TERATOMAS. E. S. NEW-
LANDS, R. H. BEGENT, S. B. KAYE, G. J.
RUSTIN & K. D. BAGSHAWE, Charing Cross
Hospital, London
Between 1977 and November 1979 we have
treated 53 patients with malignant teratomas
(43 males, 10 females). Thirty (70%O) out of43
male patients had advanced and bulky
disease at the time ofpresentation. Treatment
schedules were:
(A) Day 1: Vincristine 1-0 mg/M2; Metho-
trexate 300 mg/M2. Day 2: Bleomycin 30 mg
as an i.v. infusion for 48 h; and folinic acid
15 mg 12-hourly for 4 doses starting at 24 h.
Day 4: Cis-Platinum 120 mg/M2 with man-
nitol diuresis.
(B) VP.16.213 100 mg/M2 Days 1-5;
Actinomycin-D 0 5 mg Days 3-5; Cyclo-
phosphamide 500 mg/M2 Day 5.
(C) Hydroxyurea 500 mg q.d.s. Days 1 and
2; Vinblastine 5 tng/Mi2 Day 3; Chlorambucil
10 mg b.d. Days 3-5.
(D) The same as Treatment A without the
Cis-Platinum.
Schedules were repeated in the following
sequence: A, A, B, C, D. Courses were con-
tinued in sequence B, C, D, unless drug
resistance developed (detected by monitoring
human chorionic gonadotrophin and o-feto-
protein) and the inappropriate treatment
schedule was omitted. Of the initial 33 male
patients, 22 are off treatment (mean 9-5
months) with 19 compete responses and 3
with static C.T. Scan nodules. Life-table
analysis projects a survival of66%. Nine out
of 10 ovarian-teratoma patients are alive (1
had active disease). Toxicity was relatively
mild and febrile episodes with neutropenia
occurred in 24% of 53 patients. Adverse
prognostic factors at the time of entry were
recognized in 10 of the 11 patients who have
died.
TUMOUR-MARKER LEVELS AND
PROGNOSIS INMALIGNANT TERAT-
OMA OF THE TESTIS. R. H. J. BEGENT,
J. R. GERMA-LLUCH & K. D. BAGSHAWE,
Department of Medical Oncology, Charing
Cross Hospital, London
The effect of 6 putative prognostic factors on
survival was studied in patients with Stage
III and IV malignant teratoma of the testis.
Differences between survival curves were
tested for statistical significance. A diameter
of >5 cm in the largest tumour mass and > 8
pulmonary metastases were adverse prog-
nostic factors (P0-016 and 0-029 respectively).
Patients with malignant teratoma tropho-
blastic fared worse than those with malig-
nant teratoma undifferentiated (P 0.024)
but there was no significant difference be-
tween malignant teratoma intermediate and
either of the other two groups. Previous
chemotherapy or radiotherapy had no sig-
nificant effect.
Serum a-fetoprotein (AFP) > 103 ,ug/l and
serum f8 subunit of human chorionic gonado-
trophin (hCG) > 105 i.u./l were found to
predict a poor prognosis (P 0-001 and 0-019
respectively). A combination of measure-
ments of the tumour markers gave the most
consistent indication of prognosis, in that
patients with either AFP > 103 ,ug/l or hCG
> 105 i.u./l, or both, fared very badly com-
pared with those with neither factor
(P 0-001).
Serum concentrations of AFP and hCG
should be stated in reports of treatment of
testicular teratoma, in order to provide a
basis for comparison with other series. Regu-
lar and frequent measurements of these
markers are appropriate throughout the
whole period of clinical management of
patients with malignant teratoma.
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TRIAZINATE IN COMBINATION
CHEMOTHERAPY OF ADVANCED
COLORECTAL CANCER. M. T. SHAW,
Department of Clinical Oncology, University of
Newcastle upon Tyne (Introduced by J.
Dickson)
Baker's antifol (BAF), a triazine antifol, is a
potent inhibitor of dihydrofolate reductase,
and has shown activity against adeno-
carcinoma of the colon in man (1977, Cancer,
40, 9; Cancer Treat. Rep., 62, 553). In an
attempt to improve poor response rates ob-
tained in this disease with 5-fluorouracil (FU)
alone, 34 fully evaluable and previously un-
treated patients were treated with a com-
bination consisting of methyl CCNU 60 mg/
m2 p.o. Days 1 and 2, FU 400 mg/M2 i.v./day
for 5 days and BAF 150 mg/M2 by i.v. in-
fusion over 1 h each week. Cycles were re-
peated every 6 weeks. There were 6 complete
responses and 4 partial responses, for a total
response rate of 1800. However, 7 more
patients showed improvement. The median
duration of response was 29 weeks and the
median survival for all responders and non-
responders was 34 weeks. Toxicity consisted
of moderate neutropenia and thrombocyto-
penia, occasional skin rashes and mild oral
mucositis. Vomiting occurred in only one
patient. There seems to be no improvement
in response rate or survival with the use of
this combination over those produced by
FU alone.
SERUM cl-ANTICHYMOTRYPSIN
AND CEA LEVELS IN UPPER-GAS-
TROINTESTINAL-TRACT CANCER.
S. RASHID, E. H. COOPER, G. EAVES, J.
O'QUIGLEY & A. T. R. AXON, Unitfor Cancer
Research, University of Leeds and Gastro-
enterology Unit, General Infirmary at Leeds
In 95 patients with stomach cancer the com-
bination of the levels of the pre-operative
levels of serum xi-antichymotrypsin (ACT)
and CEA were found to be of use in prog-
nosis. The median survival in weeks according
to levels of ACT and CEA (numbers in
parentheses) were as follows: ACT <0-8 g/l,
CEA normal, 45 weeks (37); ACT >0-8 g/l,
CEA normal, 10 weeks (55); ACT >0-8 g/l,
CEA raised (>10 ng/ml, Pharmacia assay),
6 weeks (26).
This system appears to have potential for
predicting the findings at laparotomy, and
could help in clinical decision making and the
stratification of patients in postoperative
trials of chemotherapy.
These parameters were also found to be
powerful discriminants in the separation of37
cases of pancreatic cancer from 36 cases of
chronic pancreatitis. However, the serum
changes in cases of obstructive jaundice due
to gall stones were such that the combination
of ACT, CEA and routine liver-function tests
could not provide a discriminant function to
separate these three groups of diseases.
ALBUMIN METABOLISM AND DIS-
TRIBUTION IN CACHECTIC CANCER
PATIENTS. J. M. TROTTER, K. C. CALMAN,
S. GORDON, G. RAINES, J. BELL & A. FLECK,
Departments of Clinical Oncology and Patho-
logical Biochemistry, University of Glasgow
Albumin catabolism is reduced in protein-
calorie malnutrition but has been reported
high in patients with cancer. Albumin
metabolism and distribution was studied in a
group of cachectic cancer patients with
serum albumin concentrations <30 g/l to
investigate whether differences in albumin
metabolism and the acute-phase response
could be detected between patients with
anorexia secondary to disseminated malig-
nancy and those with upper gastrointestinal
lesions causing reduced dietary intake. Un-
denatured albumin was specially prepared
and labelled with 1311 (McFarlane, 1958,
Nature, 182, 53). Plasma and urinary 1311
was measured to monitor the distribution and
rate of excretion of the radioactive catabolic
products. Together with the 1311-HSA faecal
and urinary losses, the time course of dis-
appearance of 1311-HSA from the plasma was
followed until the terminal exponential was
established. The fractional catabolic rate
(FCR), transcapillary escape rate (TCER) and
the distribution of albumin (extravascular to
intravascular ratio (E/P) were determined by
compartmental analysis (Matthews, 1957,
Phys. Med. Biol., 2, 36). Six cachectic cancer
patients with > 10% weight loss and no cyto-
toxic chemotherapy in the preceding month
had an elevated FCR, TCER and E/P ratio
with an associated acute-phase response. Two
patients with reduced food intake for mech-
anical reasons demonstrated a low FCR con-
sistent with protein-calorie malnutrition, and
198ABSTRACTS OF MEMBERS' PROFFERED PAPERS
had only a rnild acute-phase response. In
addition, the survival of these two patients
was greater than 5 of the patients with high
FCR. The remaining patient responded to a
change in therapy. We conclude that cancer
patients with serum albumin < 30 g/l who
have a high FCR and associated acute-phase
response have a poor prognosis if untreated.
SERUM GLYCOPROTEIN HORMONE
a-SUBUNIT LEVELS, HORMONE RE-
CEPTORS AND DISEASE STAGING
IN BREAST CANCER PATIENTS. I. A.
MACFARLANE*, ID. BARNES*, J. M. T.
HOWATt, P. DURNINGt, C. G. BEARDWELL*
& H. BUSHt, *Department Endocrinology,
tDepartment ofSurgery and tCRCDepartment
of Medical Oncology, Christie Hospital, Man-
chester
Serum glycoprotein hormone oa-subunit was
measured in 162 consecutive, primary breast-
cancer patients (56 premenopausal), 59
patients with benign breast lumps (46 pre-
menopausal) and 112 controls (56 premeno-
pausal). Serum ox-subunit levels in the pre-
menopausal cancer patients were significantly
higher than in the controls (P 0 037; Mann-
Whitney U Test). There was no difference in
a level between the premenopausal benign
patients, the premenopausal cancer patients
and the controls (P>0.02). There was no
difference in a level between the 3 post-
menopausal groups (cancer, benign and con-
trols) (P> 0X18).
In the premenopausal cancer patients, in-
creasing disease stage (TNM cliniical staging
with histological confirmation ofnodal status)
was associated with increasing a-subunit
level (r 0 47, P=0 0001; Spearman's rank
correlation). However, in postmenopausal
patients there was no correlation between as
level and disease stage (r 0 1, P > 0-3).
The tumour cytosol oestrogen and pro-
gesterone receptor status was estimated in 40
premenopausal and 91 postmenopausal
patients. In 27 ofthese premenopausal and 41
postmenopausal patients the tumour nuclear
oestrogen-receptor status was also estimated.
No association was found between a level and
the presence of the individual receptors or
combinations of these receptors.
In view ofthe correlation of a-subunit with
disease stage, increased oa level in premeno-
pausal patients might indicate a worse prog-
nosis, as in premenopausal metastatic-melan-
oma patients (MacFarlane et al., 1979, Eur. J.
Cancer, 15, 1497).
PLASMA AMINO-ACID PROFILES IN
CANCER PATIENTS WITH WEIGHT
LOSS. J. M. TROTTER, J. E. CARLYLE. T.
HABESHAW, F. R. MACBETH & K. C. CALMAN,
Departments of Clinical Oncology and Bio-
chemistry, Gartnavel General Hospital, Glasgow
Fasting plasma amino-acid patterns in pro-
tein-calorie malnutrition have been exten-
sivelv studied, but there is little comparable
data in the cancer patient with concomitant
weight loss. Fasting amino-acid patterns were
determined in a group of 39 anorectic cancer
patients with weight loss, which exceeded
10% in the majority. None had received
chemotherapy or radiotherapy within the pre-
ceding 3 weeks. Samples were obtained
between 08:30 and 09:30 and analysed by
ion-exchange chromatography on a Locarte
amino-acid analyser (Spackman et al., 1958,
Anal. Chem., 30, 1185). Comparable sampling
was performed in patients admitted to
hospital for elective eye surgery, none of
whom were known to have systemic illness,
malignancy, or weight loss. Significantly
lower mean values for threonine, alanine,
ornithine, histidine, arginine, citrulline, eys-
tine and methionine were found in the cancer
patients, together with elevation in the mean
value of glutamic acid. Unlike pure protein-
calorie malnutrition in which levels ofbranch-
chain amino acids are low, the mean concen-
trations of leucine and isoleucine were com-
parable with controls but with twice the range
ofvalues. It is suggested that high concentra-
tions of valine, leucine and isoleucine may
reflect early protein deprivation and muscle
catabolism, whilst low levels reflect more
established cancer cachexia with greater loss
of lean body mass. In addition the ranges of
aspartic acid, asparagine, glutamine, glycine,
phenylalanine and tyrosine values were
markedly greater in the patient group.
CAE ESTIMATION IN CEREBRO-
SPINAL FLUID IN PATIENTS WITH
METASTATIC BREAST CANCER. D. P.
DEARNALEY*t, S. PATELt, T. J. POWLES* &
R. C. COOMBES*t, *Department of Medicine,
The Royal Marsden Hospital and tLudwig
Institute for Cancer Research, Sutton, Surrey.
(Introduced by G. C. Easty)
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Cerebrospinal fluid (CSF) and plasma levels
of CEA have been measured in 37 patients
with progressive metastatic breast cancer,
some ofwhom had neurological abnormalities,
and in 14 subjects with non-malignant neuro-
logical disease. Eight out of 17 patients with
CNS metastases had elevated CSF CEA levels,
together with 5/18 patients with disseminated
breast cancer but without apparent neurologi-
cal abnormality. CSF CEA was not detected
in any of the 14 patients without cancer.
Estimation of CEA in CSF may be a useful
adjunct to the diagnosis of metastatic breast
cancer involving the central nervous system.
PSYCHIATRIC MORBIDITY AFTER
CHEMOTHERAPY AND RADIO-
THERAPY FOR BREAST CANCER.
A. V. M. HUGHSON, A. F. COOPER, C. S.
MCARDLE, A. R. RUSSELL & D. C. SMITH,
Depts of Psychiatry and Surgery, Victoria
Infirmary, Glasgow
Adjuvant chemotherapy after mastectomy
may prolong disease-free survival, but there
is little information on its quality (British
Breast Group, 1976, Br. Med. J., ii, 861).
After simple mastectomy, psychiatric mor-
bidity was studied during a trial of adjuvant
chemotherapy, patients being randomized to
chemotherapy (C), radiotherapy plus chemo-
therapy (RC) or radiotherapy (R). Morbidity
was measured by a self-rating scale, the
General Health Questionnaire (GHQ) (Gold-
berg, 1972; OUP). Two groups of disease-free
survivors were compared: Group I (C and
RC) and Group II (R).
Six months after operation, GHQ scores
(Table) were similar in both groups. At 12
months, scores had risen in Group I but fallen
in Group II, the between-group difference
being highly significant. Morbidity remained
significantly higher in Group I at both 18 and
24 months after operation. Results indicate
that psychiatric illness is commoner in
patients completing a one-year course of
chemotherapy than in those who had radio-
therapy one year before, and that the differ-
ence is still evident one year later.
TABLE. GHQ scores: mean + s.e. (No. patients in brackets)
AMonths p)ost-op.
6 12
Group I 6-7 + 1-5 (26) 12-2 + 2-4 (34)
Group II 7-4+3-5(14) 2-4+0-8(18)
P N.S. < 0 001
18 24
6-5 + 2-4 (27) 4-9 + 1-6 (21)
1-4+0-6 (13) 1-0+0-7 (10)
<005 <005
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SPECIES VARIATION IN THE
METABOLISM AND EXCRETION OF
BENZO(A)PYRENE. J. K. CHIPMAN, P. C.
HIROM, G. S. FROST & P. MILLBURN, Depart-
ment of Biochemistry, St Mary's Hospital
Medical School, London
In the course of a study on the metabolism
and enterohepatic circulation of benzo(a)
pyrene (BP), the excretion of radioactivity
after i.v. administration (3 ,umol/g) of [14C]_
BP was measured in rabbits and rats. The 0
dose excreted via the bile in 6 h was 350%
(rabbit) and 550 rat). The urine was a
relatively minor excretory route in both
species. Bile samples (2 h) were incubated
with :-glueuronidase, releasing 400o of the
14C into a form extractable with ethyl acetate
at pH 7. The extracts were analysed by re-
versed-phase HPLC. Some 30% of 14C con-
sisted of polar metabolites (possibly poly-
hydroxylated and/or conjugated). In the
rabbit the major aglycone (- 350, of ex-
tracted 14C) was identified as BP 9,10-diol.
Phenols and quinones accounted for < 15%.
In rat bile extracts, however, only low levels
of the 9,10-diol were found (<3%) and the
majority of 14C cochromatographed with-
phenols and quinones (BP 3,6-quinone com-
prising up to 30%o) and w%ith the 4,5-diol
(150°). Trace amounts of 14C from both
species cochromatographed with the 7,8-diol
and with BP itself. Whether or not this
marked species difference in biliary metabo-
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lites of BP is of toxicological significance is
uncertain. It is clear, however, that the
proximate carcinogen (BP 7,8-diol) is not
excreted via the bile in appreciable quantities
either directly or as a glucuronide in either
species.
USE OF THE CANCER REGISTRY IN
THE STRATEGY OF CLINICAL
TRIALS IN LUNG CANCER THERAPY.
C. R. GILLIS*, P. BOYLE*, D. J. HOLE* & 1.
McHATTIEt, *West of Scotland Cancer Sur-
veillance Unit, Ruchill Hospital and the
tInstitute of Radiotherapeutics and Oncology,
Western Inf., Glasgow
Cancer registries which use their collected
data, particularly those derived from studies
ofaetiology, can sometimes comment usefully
on prospects for trials of therapy. Data
derived from a clinical study of immuno-
therapy, a retrospective case/control study
of cigarette-smoking habits and a prospective
population study of risk factors for chest and
heart disease, have been utilized to obtain a
representative sample of 513 cases of lung
cancer which, using the cancer registry, have
had their outcome of therapy assessed.
Treatment information was abstracted from
their case records and categorized by pre-
sence or absence of radiotherapy, chemo-
therapy, surgery and immunotherapy. Last
known survival was available from existing
case records if the patient had not been noti-
fied to the cancer registry as having died. The
most important finding requiring clarification
by prospective study was the apparent
similarity of the "no-treatment" group to all
other modalities. While the practice of
chemotherapy enhanced survival for patients
treated by surgery or radiotherapy, the differ-
ences were small. This suggests consideration
of the use of cancer registries with accurate
data to assess the outcome of therapy when
the time from diagnosis to death is short.
ULTRASTRUCTURAL CHANGES IN
THE UROTHELIUM OF RATS
ADMINISTERED N - BUTYL - N - (4 -
HYDROXYBUTYL) NITROSAMINE
(BBN). E. D. MASSEY, A. E. HARVEY, J.
CHOWANIEC & R. M. HICKS, Middlesex Hos-
pital Medical School, London
BBN induces large exophytic lesions in the
rat bladder which occur mainly in the dome
and median areas and frequently obstruct
the lumen. Well-differentiated transitional-
cell tumours were observed macroscopically
from 12 weeks onwards, with frequent in-
filtration into the core of the lesion. As time
progressed, the mature, flat hexagonal pave-
ment-like superficial cells with angular fold-
ings and ridges of normal luminal membrane
were replaced by immature cells of irregular
size and shape with a flexible luminal mem-
brane. These cells were often covered by
abnormally dense stubby and/or pleomorphic
club-ended microvilli. The latter are thought
to be indicative of malignant transformation.
Capillary endothelial cell processes were
frequently seen to breach the basal lamina and
approach the urothelium. This may be re-
lated to the development of the extensive
capillary network in these rapidly growing
tumours. There were many abnormalities at
the urothelial-mesenchymal junction: micro-
invasion by epithelial cell processes through
the basal lamina; loss, fragmentation and
invagination of basal laminae into the
epithelium and fusion of the basal laminae of
blood capillaries and urothelium. There was
frequent invasion ofthe sub-mucosa by basal-
cell pseudopodia and multicellular processes
attached to the main epithelium by a narrow
neck. As the tumours increased in size these
lesions were observed more frequently. Their
role in carcinogenesis and rapidly growing
epithelia was discussed.
AN ASSOCIATION BETWEEN PARITY
AND AGE OF PRESENTATION IN
HUMAN BREAST CANCER. S. R. SMITH,
K. L. WOODS, J. M. MORRISON* & A. HOWELL,
Departments of Medicine, Therapeutics and
Clinical Pharmacology, University ofBirming-
ham, and *Division of Surgery, Selly Oak
Hospital, Birmingham.
Early first pregnancy has been shown to
exert a protective effect against the develop-
ment of breast cancer. It has been inferred
from this that the initiation of breast cancer
occurs early in a woman's reproductive life,
and that the latency from initiation to pre-
sentation often span several decades. Al-
though the latency cannot be directly meas-
ured, any factor which markedly reduces it
would tend to result in an earlier age of pre-
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sentationi. We have therefore studied a con-
secutive series of 371 breast-cancer patients,
presenting to a single clinic over a 5-year
period, with regard to age ofpresentation and
reproductive history.
The sample was closely representative of
all breast-cancer patients presenting in the
West Midlands. The nulliparous women were
found to be significantly older at presentation
(mean age 63-1 years) than the parous women
(mean age 57-9 years; P<0001). When the
parous group was subdivided according to
the number of pregnancies, there was a pro-
gressive fall in the mean age at presentation
as parity increased. In the higher parity
groups there was a significant excess of
patients whose age at presentation was below
the median age for the group as a whole.
We conclude therefore that in a proportion
of patients the development of early neo-
plastic breast lesions is accelerated by preg-
nancy, and the effect of several pregnancies
may be cumulative. These results point to a
dual effect of pregnancy. Early first preg-
nancy reduces the risk of the initiation of
breast cancer, but when initiation has occur-
red the endocrine changes of pregnancy may
accelerate subsequent development.
STABILIZING EFFECT OF NANDRO-
LONE DECANOATE (DECA-DURAB-
OLIN, ORGANON) ON PLATELET
FUNCTION IN PATIENTS UNDER-
GOING CYTOTOXIC THERAPY FOR
BREAST CANCER. J. A. DOUBLE, M. C.
BIBBY, M. MUGHAL & R. L. TURNER, Post-
graduate School of Studies in Medical and
Surgical Sciences, University of Bradford
It has been reported that simultaneous ad-
ministration of an anabolic steroid with cyto-
toxic therapy for advanced breast cancer
reduced the toxic effects of the therapy on
marrow without apparenitly influencing anti-
tumour activity (Whyte et al., 1959, Br. Med.
J., i, 1315; Turner etal., 1979, Exp. Haenatol.,
7, Suppl. 6, 52). In order to give the maximum
dose of cytotoxic therapy it is essential fully
to monitor haemopoiesis. One of the major
complications of cytotoxic therapy is severe
thrombocytopenia and impaired platelet
function leading to harmorrhage. The present
study reports the findings from a series of
patients undergoing cytotoxic therapy for
advanced breast cancer, half of whom re-
ceived treatment with an anabolic steroid,
nandrolone decanoate (ND). The latter was
administered 200 mg weekly 14 days before
and throughout cytotoxic therapy for a
period of 10 weeks. Platelet aggregation was
measured with several inducing agents at pre-
sentation and at weekly intervals throughout
the study. At presentation some patients had
impaired platelet function. This function was
restored after 1 week in patients receiving
ND. Platelet function was maintained in
most patients receiving ND throughout the
course ofcytotoxic therapy. Patients on cyto-
toxic therapy alonie displayed inconsistent
platelet aggregation patterns.
INVESTIGATIONS INTO THE MODU-
LATION OF THYMIDINE (TdR) SAL-
VAGE BY 5-ALKYL DEOXYURIDINES.
S. E. BARRIE, A. JENEY, G. A. TAYLOR &
K. R. HARRAP. Dept of Biochem. Pharmacol.,
Inst. of Cancer Res., Sutton, Surrey
The effectiveness of antipyrimidine anti-
metabolites might be enhanced by the con-
current administration of compounds able to
modulate selectively the utilization of pre-
formed pyrimidines by tissues; either by
prohibiting in tumours, or by enhancing in
normal tissues, the "salvage" of preformed
pyrimidine. A series of 5-alkyl-substituted
deoxyuridines has been studied in relation to
the effects of these derivatives on relevant
pyrimidine biosynthetic pathways in Ehrlich
ascites cells. 5-Ethyl deoxyuridine (EUdR)
proved to be the most cytotoxic of the series
(ID50 10-5M). It was also the most effective
at inhibiting thymidine kinase, for which it is
a competitive substrate (Km 70 ,uM). Intra-
cellularly it is further converted to higher
phosph-orylated derivatives and is incor-
porated at low levels into DNA. It appears to
have two likely loci of action: inhibition of
thymidylate synthetase by its mononucleo-
tide and inhibition of TdR triphosphate in-
corporation into DNA.
An interesting tissue-specific property of
the series proved to be their competitive
inhibition ofTdR phosphorylase. This enzyme
is present in high concentrations in gastro-
intestinal mucosa and liver (Ki values for
EUdR being 0-6M and 5-2mM respectively)
but is virtually undetectable in Ehrlichl cells.
When EUdR (400 mg/kg) was adminis-
tered to tumour-bearing animals it converted
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slowly to the parent base, accompanied by a
10-fold elevation of TdR in the ascitic fluid.
These observations suggest that EUdR or
other congeners maybe ofvalue in modulating
circulating pyrimidine levels, and thus in-
fluencing the selective tissue toxicity of anti-
pyrimidines.
RECENT BIOCHEMICAL AND CHEMI-
CAL RESULTS WITH 4-(BIS-(2-BRO-
MO-PROPYL)AMINO) -2' -CARBOXY -
2-METHYLAZOBENZENE (CB 10-252).
D. E. V. WILMAN, Dept of Biochem. Pharma-
col., Inst. of Cancer Res., London
CB 10-252 was designed specifically for the
treatment of primary hepatocellular carcin-
oma (ConInors etal., 1973, J. Natl CancerInst.,
50, 243). It is chemically unreactive, but 4-
(bis-(2-bromopropyl)amino)aniline, produced
by reduction of the azo bond, is a potent
alkylating agent with a half-life of 43 sec.
The requisite enzyme, an azoreductase, is
present in liver and in hepatic tumours
(Autrup et al., 1974, Biochem. Pharrmacol., 23,
2341). In view of its short half-life the active
metabolite is rapidly detoxified upon entry
into the circulation. Azoreductase activity
has been measured in a variety of human
tumours of non-hepatic origin, carried in
immune-deprived mice. Enzyme activity
ranged between 9 and 5600 that of liver.
Preliminary investigation has demonstrated
a lack of response to the drug by these
tumours in vivo. It is inferred that CB 10-252
is likely to exhibit anti-tumour effects only in
tumours possessing azoreductase activity at
least comparable to that of liver.
Further chemical investigation of CB 10-
252 has shown it to be a mixture of two com-
ponents, separable by preparative HPLC,
which proved to be diastereoisomers. Chloro-
form solutions exhibit trans-cis photoisomer-
ism and a thermal cis-trans reaction in the
dark. The configuration ofthe azo group does
not appear to affect theability ofazoreductase
to reduce the double bond.
CB 10-252 is presently undergoing Phase
I/II clinical trial in Lusaka.
ENZYMATIC ACTIVATION OF ADEN-
INE ARABINOSIDE. A. BAXTER, H.
PARTON & J. P. DURHAM, Department of
Clinical Oncology, University of Glasgow
There has been increasing interest in the use
of adenine arabinoside (Ara-A) as an anti-
tumour agent with the development of
effective inhibitors ofthe inactivating enzyme
adenosine deaminase (reviewed by Le Page &
Khaliq, 1979, Adv. Enz. Regul., 17, 437). The
anti-tumour activity of Ara-A is generally
ascribed to the inhibition ofDNA polymerase
by the nucleoside triphosphate. Activation of
Ara-A initially requires a nucleoside kinase,
andseveral cellularnucleoside kinases, namely
adenosine kinase, deoxyadenosine kinase and
deoxycytidine kinase, have the capacity to
phosphorylate adenine nucleosides. Using
calf thymus as a control tissue, we have
shown that Ara-A is phosphorylated mainly
bydeoxyadenosine kinase, an enzyme activity
readily identifiable by polyacrylamide-gel
electrophoresis. This enzyme has also been
demonstrated in a porcine lymphosarcoma,
and its presence may be important in deter-
mining the responsiveness of a tumour to
Ara-A therapy. Some properties of deoxy-
adenosine kinase have been elucidated, in-
cluding the possibility that its activity in vivo
is regulated by another cellular protein.
HEALTH EDUCATION IN THE PRI-
MARY SCHOOL, WITH SPECIFIC RE-
FERENCE TO SMOKING. A. FARRELL,
A. L. H. CALMAN & K. C. CALMAN, Depart-
ment of Clinical Oncology, University of
Glasgow
Over the past 2 years a health-education
programme has been in production for use in
primary schools in Glasgow, its aim being to
introduce early cancer education through
smoking prevention and dietary knowledge.
Twenty primary schools are at present run-
ning the trial programme with their primary
6/7 classes (10-11 years). A further 20 schools
are involved in the teacher assessment, giving
the following sample:
Number of childlren involve(l
Number of teachers involved
Experi-
mental
group
500
225
Control
group
500
225
Evaluation aimed at teachers, parents, child-
ren and also at the effectiveness of the teach-
ing material has been carried out at all stages
of the research.
Preliminary results of a pilot study carried
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out in 1978/79 in 3 schools showed that out of
a total sample (experimental and control) of
155 children aged 9 years, almost 700o of
these had smoked at some point, of whom
5500 had smoked only experimentally, but
15% were smoking regularly. This session
1979/80, it is anticipated, with the increased
sample number, to finalize the figure obtained
in the pilot study regarding the smoking
behaviour of children of this age (10-11
years), and to evaluate further any behaviour
change brought about as a result ofthe teach-
ing programme. The teaching programme
itself is expected to undergo modification in
the liaht of results obtained from teacher
evaluation.
TUMOUR - DERIVED METABOLIC
MODULATORS. A. W. McNAIR & K. C.
CALMAN, Department of Clinical Oncology,
University of Glasgow
A cell-free preparation from TLX-5 lymph-
oma cells has been shown to affect mouse
liver metabolism (McAllister & Galman, 1975,
Br. J. Surg., 62, 161). Recent studies indicate
the presence of a factor in the tumour cell-
free preparation responsible forraising hepatic
citrate content. This factor has been found
to be: (i) destroyed by heat-treatment, (ii)
non-dialysable, (iii) precipitated by ammon-
ium sulphate fractionation, (iv) present after
ultracentrifugation at 240,000 g for 24 h,
(v) present in the growth medium of TLX-5
cells grown in vitro, and shown to be virus
free.
The effect of this factor on hepatic citrate
content is concentration-dependent. From
these observations the factor is likely to be a
tumour-derived protein and not a viral con-
taminant.
A HUMAN CELL-MEMBRANE ANTI-
GEN COMMON TO NORMAL TRO-
PHOBLAST AND TO BREAST-CAR-
CINOMA CELLS. L. C. P. SHAH & P. M.
JOHNSON, Dept of Immunology, University of
Liverpool
Rabbit antisera have been raised against both
irradiated human MCF-7 breast-carcinoma
cells and against trophoblast microvillous
plasma-membrane preparations isolated from
normal human placentae. These heteroanti-
sera were then adsorbed with immobilized
human term-pregnancy sera, placental alka-
line phosphatase and placental ferritin pre-
parations, as well as with human peripheral-
blood leucocytes. Immunofluorescence ex-
periments have shown reactivity of both
adsorbed antisera with normal trophoblast
and with breast carcinoma cells in cryostat
tissue sections, but no reactivity with other
normal human tissue. Further adsorption
experiments have confirmed the specificity of
cross-reaction of these antisera with an anti-
gen common to both normal trophoblast and
breast-carcinoma cells, and have also shown
that the cross-reactive antigen is represented
on human Jar choriocarcinoma cells and to a
lesser degree on human AV3 amniotic cells.
Cross-adsorption experiments have shown
that this antigen may not be dominant within
the antigenic specifiicites of heteroantisera
raised against MCF-7 breast-carcinoma cells
or isolated trophoblast microvillous plasma-
membrane preparations. It is possible that
this cell-membrane antigen common to both
breast carcinoma cells and normal tropho-
blast, but not to normal adult tissues, could
play a role in maternal immune responses in
pregnancy associated with anti-tumour im-
munity.
CIRCULATING IMMUNE COM-
PLEXES AND ASSESSMENT OF
TUMOUR RESPONSE IN GESTA-
TIONAL TROPHOBLASTIC NEO-
PLASIA AND MALIGNANT TERAT-
OMA. R. H. J. BEGENT & K. A. CHESTER,
Department of Medical Oncology, Charing
Cross Hospital, London
It has been suggested that concentrations of
circulating immune complexes (CIC) corre-
late with tumour response and may form
clinically useful tumour markers. This has
been tested in gestational trophoblastic neo-
plasia (GTN) and malignant teratoma (MT)
by comparison with the tumour markers
already available for these tumours. Concen-
trations ofCIC were measured byquantitating
IgG precipitated from serum by 20 poly-
ethylene glycol (Poulton et al., 1978, Lancet,
ii, 72). In GTN, high levels ofCIC were found
before treatment in 6/23 patients; in 2 of
these they fell to normal with a response to
chemotherapy, in 1 they remained raised and
the tumour failed to respond; in 3 they were
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persistently raised even thouglh complete
response (CR) was achieved. CIC levels
became raised during chemotherapy in 7/17
patients in whom they were normal before
treatment, although all achieved CR.
In MT, levels of CIC were raised before treat-
ment in 5/10 patients. In 4 they became
normal with a response to chemotherapy and,
in 1 of these, rose again on relapse. In the
remaining patient levels remained raised
although CR was achieved. In 4/5 patients
with normal levels before chemotherapy,
CIC rose during treatment, though CR was
achieved in 2, and 2 were continuing to
respond.
In 2 tumours where sensitive tumour mar-
kers are already available, CIC concentra-
tions correlated with tumour response in
some patients. However, results were mis-
leading too often for the test to be of clinical
value, and identification of the tumour-
related components is needed for more specific
assays to be developed.
T - LYMPHOCYTE LEVELS IN
PATIENTS WITH HODGKIN'S AND
NON-HODGKIN'S LYMPHOMAS. S.
KADHIM, R. C. REES, B. W. HANCOCK, R.
WALKER & C. W. POTTER, Department of
Virology, The University Sheffield Medical
School, Sheffleld
The total number of T lymphocytes in the
peripheral blood of24 patients Mith Hodgkin's
lymphoma and 52 patients with non-
Hodgkin's lymphoma was compared to that
of 81 controls, using spontaneous sheep red-
blood-cell rosetting techniques (E-SRBC).
The percentage of rosette-forming lympho-
cytes was estimated for high-affinity T
lymphocytes (29°C) and compared with that
of low affinity T lymphocytes (4°C).
Hodgkin's and non-Hodgkin's lymphoma
patients showed a decreased ability to rosette
at 29°C and 4°C when compared with con-
trols, although more rosette-forming cells
were seen at 4°C than at 29°C in both normal
controls and in lymphoma patients. Further
groupings of patients according to age of
disease seemed to indicate deviations in the
increase of rosette-forming cells, at 290C to
4°C, compared with increases in controls.
Pre-treatment of lymphocytes with neur-
aminidase increased the number of low- and
hiogh-affinity rosettes in both patients and
controls, but this test could not be used to
discriminate between cancer and non-cancer
subjects.
INHIBITION OF THE PRODUCTION
OF COLONY-STIMULATING FACTOR
BY PHAGOCYTOZING NEUTRO-
PHILS. J. FLETCHER, M. A. PHILIP & G.
STANDEN, Clinical Haematology Unit, Depart-
ment of Therapeutics, City Hospital, Notting-
ham
A humoral factor, produced by monocytes
and macrophages, known as colony-stimu-
lating factor (CSF) is necessary for the
growth of granulocyte/macrophage colonies
in agar culture, and probably for granulo-
poiesis in vivo. We now report that production
of CSF by mononuclear phagocytes is in-
hibited by a substance released from phago-
cytosing neutrophils, but not from resting
neutrophils. Phagocytosis releases as much
inhibitory activity as disruption of the cells
by sonication. Inhibitory activity released by
106 neutrophils/ml can be detected after 100-
fold dilution. The inhibitor is heat-labile (30
min at 60°C) and non-dialysable. The amount
and kinetics of inhibitor released during
phagocytosis are the same as transcobalamin,
which suggests that both are constituents of
the neutrophil's secondarv or specific gran-
ules.
ANTIBODY-DEPENDENT AND SPON-
TANEOUS CYTOTOXICITY IN
HODGKIN'S DISEASE AND CON-
TROL SPLEEN TISSUE. S. AL SAM, D. B.
JONES, S. V. PAYNE & D. H. WRIGHT,
University Department of Pathology, General
Hospital, Southampton
To date, studies of cytotoxic effector func-
tion in Hodgkin's disease have relied mainly
on peripheral blood as a source of lympho-
cytes (Holm et al., 1975, Clin. Exp. Immunol.,
21, 276). Marked changes in lymphocyte sub-
populations are however detectable in the
spleen before tumour involvement, and have
been implicated in the pathogenesis of the
disease (Payne et al., 1976, Clin. Exp.
Immunol., 24, 280). We report preliminary
results of a study of cytotoxic effector func-
tion in HD spleen-measured by 51Cr release.
Spontaneous cell-mediated cytotoxicitv at
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an effector:target ratio of 20:1 against the
erythromyeloid line K562 is significantly in-
creased (41-4 + 7-1) in 5 non-involved HD
spleens by comparison with control tissue
(19.1 + 1.2; P<0 01) and antibody-dependent
cytotoxicity against the nucleated target Raji
was similarly raised (43.9 + 96/205 + 13-1;
P <0.05). These increases were not correlated
with an increase in FCG-positive cells.
ADCC against chick red-blood cells, an
effector function depleted on Sephadex GIO,
in parallel with nonspecific esterase-positive
macrophages, was marginally though not sig-
nificantly increased (72 6 + 12-8 vs 60-3 + 3.3
at an effector: target ratio of 10:1) in HD.
These results imply either the sequestra-
tion of lymphocytes capable of spontaneous
and antibody-dependent cytotoxicity in the
spleen in HD, or enhancement of the effector
capacity of an indigenous population of cells
by local immunostimulation.
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